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Abstract 
Purpose: The delivery of post-mastectomy radiotherapy (PMRT) with bolus electron conformal 
therapy (BECT) for patients with left-sided breast cancer can reduce second cancer complication 
probability (SCCP) compared to modern rotational intensity modulated x-ray (IMXT) techniques 
such as volumetric modulated arc therapy (VMAT) or Tomotherapy. However, rotational IMXT 
yields superior levels of dose homogeneity compared to BECT. This study investigates the use of 
intensity modulated (IM) BECT (IM-BECT) to improve dose homogeneity in the chest wall 
(CW) region of the PMRT planning target volume (PTV) abutted to parallel opposed IMXT 
tangents for the remaining PTV for a clinically-representative set of patients, and quantitatively 
compares treatment planning metrics of BECT+IMXT to IM-BECT+IMXT.  
Methods: Nine left-sided PMRT patients previously treated with VMAT at the Mary Bird 
Perkins Cancer Center were included in this study. PTVs included the CW and regional lymph 
nodes. BECT+IMXT and IM-BECT+IMXT plans were constructed with a commercial IMXT 
treatment planning system, a research version of a commercial BECT planning system (modified 
to support IM-BECT planning), and a treatment planning strategy developed in this study. The 
resulting plans were compared based on PTV dose homogeneity index (DHI) and conformity 
index (CI), tumor control probability (TCP), dose to organs at risk (OAR), normal tissue 
complication probability (NTCP), and SCCP. Statistical significance of differences between 
BECT+IMXT and IM-BECT+IMXT plans were tested using the two-way Wilcoxon Signed 
Rank test (p<0.05).  
Results:  The IM-BECT+IMXT treatment plans provided significantly lower volumes receiving 
107% and 110% prescribed dose (i.e. V107% and V110%) in the electron subtarget (e-Target), the 
volume of the PMRT PTV treated with electrons. At a prescribed dose of 50 Gy, the average 
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V107% and V110% decreased from 10.6% and 2.9% with BECT+IMXT to 2.2% and 0.2%, 
respectively, with IM-BECT+IMXT. The IM-BECT+IMXT treatment plans also provided 
significantly lower maximum dose to the lung (Lung-Dmax). The average Lung-Dmax decreased 
from 45.7 Gy with BECT+IMXT to 44.8 Gy with IM-BECT+IMXT.   Both BECT and IM-
BECT plans produced potentially clinically acceptable PMRT plans with no less than 99.0% 
TCP. 
Conclusion:  Both BECT+IMXT and IM-BECT+IMXT provided acceptable PMRT treatment 
plans for the patients included in this study. However, IM-BECT+IMXT showed a statistically 
significant advantage in terms of e-Target dose homogeneity.  
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Chapter 1. Background 
 
 
As of 2016 breast cancer is the most frequently diagnosed cancer among women, 
accounting for 29% of new cancers, and is second (14%) only to lung cancer (26%) in claiming 
the highest portion of cancer related deaths.  Despite this high incidence and mortality, it is 
remarkable that curable, early stage disease tops the distribution of female breast cancers (65%) 
compared to higher risk stages: regional lymph node involvement (16%) and distant metastases 
(16%).  Moreover, five-year relative survival for female breast cancer has increased from 75% in 
1977 to 91% in 2011, an indication that the large number of breast cancer related deaths stem 
from sheer breast cancer incidence. (Siegel 2016) 
 Radiation therapy (RT) treatment side effects of any form are a concern and must not 
outweigh the benefits of therapy. Refinements in RT techniques and the high incidence and 
curability of breast cancer elevate concern for less common treatment side effects, such as 
radiation induced second cancers or non-life-threatening psychological trauma like poor breast 
cosmesis. Post-mastectomy radiation therapy (PMRT) with modern intensity modulated (IM) 
rotational photon beam techniques, such as helical Tomotherapy and Volumetric Modulated Arc 
Therapy (VMAT), have been shown to deliver more conformal and homogeneous chest wall 
(CW) doses than conventional mixed beam techniques (Ashenafi 2010, Nichols 2014), possibly 
providing a benefit to expected cosmesis. However, these authors also showed that compared to 
conventional mixed-beam techniques that incorporate electron fields, the modern techniques also 
have 2 to 3 -fold increased risk of late effect second cancer complication probability (SCCP).  
This work is focused on PMRT treatment planning for a modified form of an advanced 
conventional mixed-beam technique, IM bolus electron conformal therapy (BECT), which 
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should offer both improved dose conformity and homogeneity compared to conventional mixed-
beams, without increasing SCCP. BECT is an electron irradiation technique suitable for CW 
treatment (Perkins 2001, Kim 2012, Opp 2013) that increases dose conformity compared to 
electron beams regularly used in conventional plans. The current research project is a treatment 
planning study to confirm the benefit of an IM BECT (IM-BECT) technique with respect to dose 
uniformity for left-side CW irradiation targets. The goal was to show that the dose spread within 
the planning target volume (PTV) can be reduced to achieve a better plan quality than standard 
BECT without reducing other metrics of plan quality such as PTV coverage or normal tissue 
(NT) sparing.  
1.1 Mastectomy and Chest Wall Irradiation 
According to Surveillance Epidemiology & End Results (SEER) data, the rate of 
mastectomy decreased from 1980 to mid-2000 following the NIH endorsement of breast 
conservation surgery (BCS), which is a more cosmetic surgical option for patients with early 
stage cancer (Kummerow 2015). Patients undergoing BCS or mastectomy both receive RT for 
local and regional control (i.e. control of any remaining viable cancer cells in local breast tissue 
and regional LN) and systemic chemotherapy for control of distant metastases.  Patients 
receiving BCS attain similar 20 year disease free OS rates (85%) as those treated with 
mastectomy (Siegel 2016), but for unclear reasons the rate of mastectomy began increasing again 
in 2005 (Kummerow 2015). 
Because breast cancer may spread to regional lymph nodes (LN) it is common for 
patients to undergo a mastectomy followed by RT. Analysis of several clinical trials by the Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG) has shown that PMRT improves local 
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regional control with a two-thirds reduction in failures and has improved ten-year overall 
survival (OS) by 3.7% compared to surgery and chemotherapy alone (Chung 2007).   
Per National Comprehensive Cancer Network (NCCN) clinical practice guidelines in 
radiation oncology and the National Institutes of Health (NIH), PMRT targeting the CW and 
regional LN is indicated for disease stages including: a primary tumor with major axis >5 cm 
(T3), a primary tumor which has spread to chest wall (T4), or involvement of ≥4 cancer positive 
axillary LN (≥pN2). The 2014 NCCN guidelines further recommend a strong consideration of 
PMRT for subgroups of earlier stage disease (e.g. 1-3 positive axillary LN when surgery 
precedes chemotherapy). (Hernandez 2014) 
1.2 PMRT Irradiated Areas 
The most common areas of local-regional recurrence following mastectomy are the CW 
wall (50% of failures) and the clavicular LN (41% of failures) regions (Pierce 2001). The 
radiotherapy PTV commonly includes the CW, axillary (AX) LN, supraclavicular (SC) LN, and 
less commonly, the internal mammary chain (IMC) LN (van der Laan 2010), also referred to as 
the internal mammary nodes (IMN).  A patient surface rendering depicting a “bird’s eye view” of 
an example PMRT treatment field is shown in Figure 1.1. The field covers the SC superiorly 
with the inferior CW border matching the apparent loss of breast tissue compared to the 
contralateral side.  The medial border covers the deeper IMC and the lateral border covers the 
AX running to the mid-axillary line.  Anteriorly the treatment volume includes the skin surface 
and posteriorly it approaches the interface with the lung and rib cage. It is important to include 
areas of surgical scarring within the irradiated area and to deliver an adequate skin dose through 
use of a bolus material (blue dot outline) placed in direct contact with the patient. Bolus is a 
tissue equivalent material which is placed in direct contact with or near a patient surface. While a 
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uniform thickness bolus often serves to increase dose to skin, which would otherwise remain in a 
surface dose build-up region (Hernandez 2014). 
1.3 Radiation Dose and Complications 
Common dose prescriptions are 1.8-2 Gy per fraction to a total dose of 45-50 Gy (NCCN 
2016).  In electron beam therapy, dose is prescribed to a physician selected isodose line (IDL), 
typically the 90% IDL.  The delivery of highly conformal and homogeneous PTV dose 
distributions spare organs at risk (OAR) and reduce NT side effects including poor cosmetic 
outcome. The OAR are predominantly the heart and lung, but other areas of concern include: 
contralateral breast, spinal cord, esophagus, brachial plexus, bone, and skin. There is added 
Figure 1.1 Post-mastectomy field incident on the left breast to treat the SC: supraclavicular 
lymph nodes; AX: axillary lymph nodes; CW: chest wall; IMN: internal mammary chain 
lymph node. Adapted from (Hernandez 2014) 
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difficulty for left-side breast cancers or PTVs when the latter include the IMN, increasing the 
irradiated heart volume. 
Exposure of the heart to high dose can cause late effect cardiovascular diseases such as 
pericarditis, congestive heart failure, and coronary atherosclerosis; however, doses below 30 Gy 
to the heart pose no increased risk of cardiac mortality (Gagliardi 1996). A large irradiated 
volume of lung can cause acute inflammation, termed pneumonitis, or the scarring and stiffening 
of lung tissue, termed pulmonary fibrosis (Pierce 2001). The percent volume of lungs given 20 
Gy or more (V20Gy) is a parameter used to compare the risk of pneumonitis during treatment 
planning (Hernandez 2014). 
1.4 PMRT Techniques 
1.4.1 Orthovoltage Era and Cobalt-60 
Early PMRT external beam radiation techniques (1920-1940) used orthovoltage (200-500 
kVp) x-rays, which are characterized by rapid distal dose falloff in soft tissue and high 
absorption in bone that resulted in poor dose homogeneity with depth and increased 
osteoradionecrosis, respectively. Cobalt-60 teletherapy (1950-late 1900) resolved these 
limitations, but for the better part of its period of use, lacked the robustness of computed 
tomography (CT) dose calculation, which did not see wide use until the 1980s. In addition, these 
traditional techniques suffered from field abutment issues which remain for conventional 
techniques used today. (Bernier 2004) 
1.4.2 Megavoltage Era 
With the arrival of mega-voltage (MV) linear accelerators (1970 – present) came 
conventional mixed-beam techniques, many which are 3D conformal radiation therapy (3D-
CRT) techniques stemming from 60Co beam arrangements. Conventional mixed-beam 
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arrangements delivered with a linear accelerator benefit from both higher energy photon beams 
with better flatness and penetration, and electron beams with finite ranges that are capable of 
sparing distal tissues. 
Common conventional mixed-beam techniques using linear accelerators were analyzed 
by Pierce et al. (2002) using dose-volume histograms (DVH) and the biological metric normal 
tissue complication probability (NTCP) for heart and lung. In Pierce’s findings the heart NTCP 
and the volume receiving ≥30 Gy (V30Gy) were significantly higher for 60Co plans than all other 
plans. Pierce also determined that standard medial and lateral MV photon tangents with non-
divergent beam edges for heart sparing abutted to anterior MV photons for the SC yielded the 
lowest lung NTCP. However, Pierce concluded that there is no “gold standard” arrangement for 
all cases and that the choice of technique depends on body habitus (i.e. body mass index), PTV 
proximity to the heart, and clinical experience. (Pierce 2002) 
The greatest obstacle for conventional mixed-beam techniques are field abutment dose 
heterogeneities. To reduce their impact there are many modifications one can make to the 
technique; the most notable being IM of beams in the abutment region (Lichter 1983, Li 1999, 
Wright 2014). Field abutments are unavoidable with typical conventional PMRT techniques due 
to the mixed-beam arrangements required to spare OARs and conform the dose to the PTV.  
Examples of two types of field abutment heterogeneities are shown in Figure 1.2, which 
depicts a dose distribution attained by Ashenafi et al. (2010) using a conventional PMRT mixed-
beam technique. First, the abutment of an anteroposterior (AP) 12 MeV electron beam for the 
IMC with an AP 9 MeV electron beam for the medial CW achieved a variable treatment depth at 
the medial IMC-CW interface; however, the unmatched electron beam penumbras led to a 
moderate medial hotspot in the field junction. Second, the medial 9 MeV electron beam abutted 
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to an oblique (30°) 9 MeV electron beam for the lateral CW resulted in a more significant hot 
spot due to beam overlap (Hogstrom 1991, Ashenafi 2010).Each of the hotspots in Figure 1.2 
were acceptable tradeoffs of the gains in PTV coverage and normal tissue sparing with the use of 
mixed-beams.  However, there is the potential for unacceptable elevations in the magnitudes of 
the field abutment dose heterogeneities due to small setup errors made when the treatment fields 
are delivered. A cumbersome approach to smoothing out the field abutment dose inhomogeneity 
and reducing the impact of setup uncertainty is to move field match-lines 0.5 to 1.0 cm weekly or 
biweekly throughout a course of treatment. 
 
Figure 1.2 Hot spots in a conventional mixed beam plan, generated by Ashenafi, consisting 
of a 12 MeV electron beam IMC field, a 9 MeV electron beam medial CW field, and a 9 
MeV electron beam lateral CW field (Ashenafi 2010). 
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1.4.3 Electron Arc Therapy 
In the 1980s Leavitt et al. (1985) implemented PMRT using electrons for the CW, 
delivered by a conventional linac, with a rotational technique that abrogated electron field 
abutments and was highly effective in clinics where it was employed (McNeely 1988, Gaffney 
1997) especially for patients with barrel-chested anatomy or a posterior scar (Leavitt 1985, 
Gaffney 2001). Gaffney et al. (Gaffney 2001) have reported on their 20 years of experience, 
where they observed lower rates of recurrence for their patients treated with electron arc therapy 
compared to patients in other clinical trials that had a better prognosis and who were treated with 
3D-CRT. Stratified by level of LN involvement, Leavitt and Gaffney’s rates of 10-year actuarial 
local-regional control were 100, 93, 98, and 89% for 0, 1-3, 4-9, and ≥10 positive lymph nodes. 
The predominant acute effect for their electron arc cohort was skin toxicity of grade 1 (faint 
erythema or dry desquamation) in 52% of patients and of grade 2 (moderate to brisk erythema or 
a patchy moist desquamation confined to skin folds and creases; and/or moderate edema) in 42% 
of patients. Though electron arc is a suitable PMRT technique, wide clinical usage is impeded by 
a lack of a commercially available treatment planning system with support for electron arc dose 
calculation and a dynamic multi leaf collimator (Leavitt 1989). 
1.4.4 IMRT, VMAT, and Tomotherapy 
Intensity modulated radiation therapy (IMRT) is a technique that utilizes a dynamic 
photon MLC—with commercial availability—to modulate photon beams from multiple source 
positions. IMRT dose distributions have been shown to surpass the level of target dose 
homogeneity and sparing of OAR that is achievable with conventional techniques for left-side 
PMRT (Zhang 2015). However, CW irradiation using IMRT does have some potential issues 
including the accuracy of treatment planning system dose calculation in superficial target 
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volumes (Cheek 2008). There is also concern that respiratory motion could lead to a 
displacement of the CW target outside of the irradiated region (Ito 2011). The customary clinical 
solution to each of these problems is to plan and treat with 1 cm bolus over the CW which allows 
for an extension of the CW PTV into the bolus material 
Since mid-2000, two forms of advanced IMRT: VMAT and helical Tomotherapy, have 
become available and are now the primary techniques used at the Mary Bird Perkins Cancer 
Center (MBPCC) in Baton Rouge, LA (Heins 2016). VMAT is a method of delivering a 
continuous arc with a conventional linac as a dynamic MLC modulates photon fluence (Yu 
1995). Helical Tomotherapy incorporates a fan shaped beam from a Tomotherapy linac to deliver 
an arc as the patient is translated though the plane of rotation of the fan beam and a binary MLC 
modulates photon fluence (Mackie 1993). Ashenafi and Nichols (Ashenafi 2010, Nichols 2014) 
have shown that Tomotherapy and VMAT produce marginally higher quality PMRT plans in 
terms of dose heterogeneity and dose conformity than conventional mixed-beams.  
Nichols (2014) also demonstrated that VMAT plans produce comparable dose 
distributions to Tomotherapy in the setting of PMRT, albeit with a small degree of dose spill, as 
shown in Figure 1.3.  Comparing VMAT and Tomotherapy based on PTV coverage, dose 
homogeneity index (DHI), conformity index (CI), dose to OAR, Nichols found that VMAT, in 
roughly 1/3 of the Tomotherapy treatment time, provided better CI and slightly better low dose 
sparing of OARs and that Tomotherapy showed slightly better DHI and high dose sparing of 
OARs. Additional comparisons of biological metrics: NTCP, SCCP, and tumor control 
probability (TCP) for the two techniques showed equivalent TCP (nearly 100%) and the same 
NTCP for heart and lung (approximately 1%); however, VMAT showed a small but statistically 
significant reduction of SCCP compared to Tomotherapy.  
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Prior to Nichols (2014) finding the two techniques roughly equivalent in the setting of 
PMRT, Ashenafi (2010) had reported on Tomotherapy compared to a conventional electron 
technique. He observed that while Tomotherapy benefits from better homogeneity in the CW and 
IMC targets, elimination of field abutments, and a smaller V20Gy for ipsilateral lung the two  
techniques were similar in terms of the volume of heart receiving ≥15 Gy (V15Gy) and in terms of 
biological metrics of NTCP for radiation pneumonitis and cardiac mortality. However, Ashenafi 
Figure 1.3 Axial and coronal isodose curves for PMRT treatments: VMAT (a,b), Helical 
Tomotherapy (c,d) achieved by Nichols et al. (Nichols 2014) 
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(2010) also reported that Tomotherapy plans produced larger volumes of low dose to 
contralateral breast (CB) and contralateral lung, and a larger normal tissue (NT) volume 
receiving 5-25 Gy, resulting in larger SCCP. Combining his own results with Ashenafi (2010) 
findings, Nichols (2014) reported that PMRT performed with VMAT or Tomotherapy each result 
in contralateral breast SCCP up to two times that of PMRT delivered with a conventional mixed-
beam technique. Hence, the question is raised of whether there be a technique that has the 
benefits of rotational IMRT (VMAT, Tomotherapy) and the low SCCP from using electron 
beams. This contributes to the impetus to study a mixed beam electron technique that replaces 
abutted electron fields at differing energies with a single bolus assisted electron conformal 
therapy field.  
1.4.5 Bolus Electron Conformal Therapy 
Bolus electron conformal therapy (BECT) as defined by Hogstrom (Hogstrom 2003) is 
the use of a single energy, variable-thickness-bolus assisted electron beam to shape distal 90% 
dose to the PTV and minimize dose to underlying NT. BECT technology is commercially 
available from .decimal (dot decimal), LLC. (.decimal, LLC., Sanford, FL), which provides it’s 
free p.d® (p dot d) treatment planning software based on Low et al. (Low 1992) bolus design 
operators. As an additional service .decimal markets the wax bolus material milled according to 
custom, patient specific, p.d bolus designs. The use of BECT is well documented in the setting of 
PMRT (Perkins 2001, Kim 2012, Opp 2013), as well as, other sites such as  paraspinal muscles 
(Low 1995) and head and neck (Kudchadker 2003). Figure 1.4 illustrates a PMRT patient setup 
with a variable thickness bolus and the corresponding dose plan using BECT. Opp et al. (2013) 
compared BECT to other conventional PMRT techniques such as field-in-field modulated and 
wedged tangents, as well as to an 8-field IMRT technique. It was found that BECT obviates the  
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Figure 1.4 Birds eye view of a Bolus ECT setup for post-mastectomy chest wall. a) Variable 
thickness bolus (blue) over the left chest wall (CW). b) BECT dose plan showing conformity 
of the 90% (50 Gy) isodose line (blue) with respect to the PMRT planning target volume 
(green). Additional isodose lines are: 110% (red), 50% (green), and 10% (pink). (Opp 2013) 
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need for IMN-CW field abutments and results in less exposed lung compared to wedged or field-
in-field photon tangents. Opp (2013) also showed that while BECT is slightly less conformal 
than IMRT, it results in much less volume of contralateral breast and lung receiving low dose 
baths. However, these BECT gains come with the drawback of increased dose heterogeneity in 
the PTV compared to a single electron beam dose distribution in a water phantom. This type of 
heterogeneity is due to multiple Coulomb scattering (MCS) and an irregular wax bolus source-
surface-distance (SSD). The use of BECT can result in MCS and an irregular bolus SSD which 
increase the normal 10% (90%-100%) dose spread measured in a water phantom to up to 20% 
(Kudchadker 2002). 
1.5 Research Significance and Objective 
LSU and MBPCC have an ongoing research program to improve PMRT. Two rotational 
IMRT techniques, helical Tomotherapy (Ashenafi 2010) and VMAT (Nichols 2014) have been 
shown to deliver marginally more conformal and homogeneous doses compared to conventional 
techniques, but usually at the expense of at least doubling SCCP. Heins (2016) showed that using 
BECT for the inferior CW PTV and parallel opposed x-rays for the superior CW offers 
improvements in PMRT dose conformity like rotational IMRT techniques without adding to 
SCCP and using a single BECT field eliminates hot/cold spots due to lateral field abutment. 
However, dose heterogeneities from the irregular bolus surface remain unless the BECT 
technique is mixed with VMAT (80% BECT, 20% VMAT), which adds SCCP. 
 The present treatment planning study takes an alternative approach to Heins (2016) to 
study PMRT using BECT to treat the inferior portion of the CW PTV with an intensity 
modulated electron beam. First, the BECT dose plan will be homogenized using intensity 
modulated BECT (IM-BECT) taking advantage of the work of Kudchadker et al. (2002). Second, 
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the superior PTV will be treated using parallel opposed, oblique, and IM x-ray beams where IM 
will minimize the dose heterogeneity due to variable patient thickness superiorly and in the 
abutment region inferiorly. The objective of this treatment planning study is to compare left-side 
CW PMRT plans with IM-BECT+IMXT to plans with BECT+IMXT, and to establish any 
benefit of IM-BECT from statistically significant and clinically significant differences in metrics 
of plan quality. For the mixed-beam plans in this study, the BECT components are planned in a 
modified research version of p.d v5.1, which allowed the generation of a forward planned—not 
inversely optimized—intensity profile (i.e. a desirable intensity that could be delivered with 
electron beam IM) and subsequent calculation of the IM-BECT dose distribution. 
1.6 Hypothesis and Specific Aims 
1.6.1  Hypothesis 
For nine post-mastectomy radiotherapy (PMRT) left-side chest wall (CW) patients 
previously treated with volumetric modulated arc therapy (VMAT), treatment plans using 
intensity modulated bolus electron conformal therapy (IM-BECT) abutted to intensity modulated 
x-ray therapy (IMXT) will be statistically superior to plans using bolus electron conformal 
therapy (BECT) abutted to IMXT. 
1.6.2 Aim 1 – Development of Treatment Planning Strategy 
Using a subset of three patients, develop a potentially clinically acceptable treatment 
planning strategy for either an IM-BECT or BECT field that treats an inferior portion of the left 
CW planning target volume (PTV) abutted to parallel opposed IMXT beams, which treat any 
remaining PTV (superior CW, supraclavicular nodes (SC), axillary nodes (AX), and internal 
mammary nodes (IMN)).  Trial plans will be evaluated using specific PMRT PTV coverage and 
organs at risk (OAR) dose metrics. 
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1.6.3 Aim 2 – Generate Treatment Plans and Plan Metrics 
Generate BECT+IMXT and IM-BECT+IMXT treatment plans for the remaining six 
patients using the strategy developed in Aim 1. For all patients, calculate dose metrics for the 
inferior-left CW electron PTV subtarget, the PTV, and specific OARS, as well as biological 
metrics such as tumor control probability (TCP), normal tissue complication probability (NTCP), 
and second cancer complication probability (SCCP). 
1.6.4 Aim 3 – Test for Statistical Significance of Metrics 
Primary Goal 
For BECT+IMXT and IM-BECT+IMXT treatment plans, compare the metrics calculated 
in Aim 2 for statistically significant differences.  
Secondary Goal 
For retrospective VMAT treatment plans generated for a prior left-side PMRT study 
(Heins 2016) on the same patient cohort as the retrospective treatment plans generated in this 
study, compare IM-BECT+IMXT plan metrics calculated in Aim 2 for statistically significant 
differences with VMAT plans metrics calculated by Heins (2016).  
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Chapter 2. Aim 1 – Development of Treatment Planning Strategy 
 
The purpose of Aim 1 was to develop a treatment planning strategy that would yield 
clinically acceptable results for BECT+IMXT and IM-BECT+IMXT treatments. There were 
three central tasks in developing this strategy: 1) determine which electron beam energy to use, 
2) determine an acceptable electron and x-ray beam arrangement, and 3) implement electron 
intensity modulation into the IM-BECT planning process. It was expected that the use of higher 
energy for a left anterior oblique (LAO) electron beam would allow for an unknown, but 
increased amount of the superior, deeper portions of the PTV irradiated with BECT or IM-
BECT; however, it also presented a concern for increased electron dose in NT (lung and heart). 
Therefore, an energy study was performed using a subset of three patients (CW2, CW3, and 
CW6). For these patients plans, BECT and IM-BECT trial plans were developed using 13, 16, or 
20 MeV electron energies. These plans consisted of the LAO electron beam abutted to parallel 
opposed wide IMXT tangents consisting of a 6 MV right anterior oblique (RAO) termed 6MV-
RAO and a 10 MV left posterior oblique (LPO) beam termed 10MV-LPO. After a review of the 
BECT+IMXT and IM-BECT+IMXT trial plans, one modification to the IMXT beam 
arrangement was the addition of a third 6 MV anteroposterior (AP) IMXT field termed 6MV-AP. 
This was done for one patient, CW2, due to a high esophagus dose compared to the other two 
patients. 
2.1 Methods 
Composite treatment planning for the BECT/IM-BECT+IMXT techniques was 
performed using the Pinnacle3 v9.8 (Philips Radiation Oncology Systems, Fitchburg, WI) 
treatment planning system (TPS). Bolus design and dose calculation for the BECT and IM-
BECT beam were performed in a research version of p.d v5.1. All composite plans were 
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designed to deliver a prescribed homogeneous dose of 50 Gy in 25 fractions to the PTV and then 
normalized such that 95% prescribed dose (47.5 Gy) or more was given to 95% of the PTV as 
read from the dose volume histogram (DVH). 
2.1.1 Patient Selection 
The current study utilized nine left-side PMRT patients who (1) received prior treatment 
with VMAT at the Mary Bird Perkins Cancer Center following a left-side mastectomy, (2) were 
part of a HIPAA compiled data set, and (3) were the subjects of a previous retrospective PMRT 
treatment planning study (Heins 2016). Continuing with the previous patient identification 
scheme, the nine anonymized patient data sets are referred to by their unique research identifiers 
CW1-CW9. Each data set included CT images and contours. The CT images had been acquired 
with a 120 kVp large bore GE LightSpeed 16 CT scanner (General Electric Medical Systems). 
For Aim 1, three of the nine patients (CW2, CW3, and CW6) were selected to develop an 
acceptable PMRT treatment planning strategy. The three patients used for this aim were selected 
in numerical order from CW1 through CW9, choosing the first three, for which a 13 MeV 
electron beam was sufficient for electron coverage of the PTV to the superior extent of the heart.  
2.1.2 Patient Contours 
Delineation of the PTV and organs at risk (OAR) was performed by a radiation oncologist at the 
initial time of clinical VMAT planning. These contours, included in the anonymized patient data 
sets, were used for Aim 1. The clinically defined PTV for each patient included the chest wall 
(CW), supraclavicular (SC) lymph nodes, axillary (AX) lymph nodes, internal mammary chain 
(IMC) lymph nodes, and a 1 cm thick Superflab bolus placed over the chest at time of 
simulation. The primary OAR contours obtained with each patient included ipsilateral and 
contralateral lungs, whole heart, contralateral breast, esophagus, trachea, and spinal cord. Other 
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regions of interest (ROI) included myocardium, an external skin contour (ECT Skin), and a 
contour of the 1 cm Superflab bolus (Superflab). To evaluate the dose to the patient, a PTV 
Evaluate contour was also included. PTV Evaluate was the PTV drawn by the physician less the 
1 cm Superflab; henceforth, PTV Evaluate is referred to as the PTV. For Aim 1, the PTV was 
subdivided into an inferior CW subtarget, a field junction subtarget, and a superior subtarget 
(process described in 2.1.5). The BECT or IM-BECT plan component targeted the inferior CW 
subtarget (e-Target). An IMXT plan component targeted the superior subtarget (γ-Target) and a 3 
cm region adjoining the e-Target and γ-Target, i.e. the field junction subtarget (JCT). Figure 2.1 
depicts an example of the PTV in a sagittal plane and its division into the e-Target, JCT, and γ-
Target. 
2.1.3 Electron Beam Arrangement 
To perform bolus design for left-side PMRT BECT and IM-BECT, an electron beam was 
first defined as a component of a composite plan in Pinnacle. Once the beam parameters such as 
Figure 2.1 PTV, e-Target (blue), JCT (green), and γ-Target (yellow) PTV subtargets 
superimposed on sagittal CT plane through the heart. 
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gantry and table angles, isocenter, source-surface-distance (SSD), and field shape were defined, 
the patient data was exported to p.d for bolus design. The methodology presented here was used 
for selection of the geometric electron beam parameters.  
2.1.3.1 LAO Electron Gantry and Table Angle Selection 
The electron beam gantry was initially chosen such that the beam central-axis (CAX) was 
positioned approximately “normal” to the proximal PTV surface, as shown in Figure 2.2, in a 
transverse CT slice approximately mid-way through the PTV. For the three Aim 1 patients, this 
resulted in electron beam gantry angles in a range of 38-45°. The electron beam table angle was 
set to 0°±10having little possibility of patient or table collision with the gantry of the IMXT 
tangents. 
Figure 2.2 Transverse CT plane showing alignment of electron beam CAX approximately 
normal to the PTV (green). Electron beam CAX and applicator edges are shown as white 
dashes. Aperture edges demarked by solid-blue lines and isocenter labeled as “Iso1_e”. SSD 
105 cm to patient surface. 
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2.1.3.2 Electron Beam Isocenter and SSD Selection 
The electron beam CAX was then positioned near the center of the PTV, as observed in 
the beam’s eye view (BEV) in Figure 2.3(a). Then, the SSD (i.e. source-to-patient skin surface 
distance) was set to 105 cm, allowing for electron applicator clearance of wax bolus. Electron 
fields were planned using physical Cerrobend blocks and often the final electron field shape was 
Figure 2.3(a-c): (a) Initial electron aperture: CAX at the center of the PTV (green) with a 1.5 
cm field margin. (b) 13, 16, and 20 MeV loss-of-coverage locations (purple, orange, and 
green, respectively). (c) Example of an energy specific electron beam aperture for 20 MeV e-
Target (blue).  
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nearly half beam blocked (HBB). In such cases, the isocenter was moved superiorly and the 
block was recreated to yield a HBB electron beam edge, provided the maximum field size (26.5 
x 26.5 cm2) was sufficiently large. This was usually only possible when using 13 MeV (i.e. the 
smallest e-Target with respect to electron energy).  
2.1.3.3 Estimation of Superior Electron Beam Coverage 
The intent of the strategy was to cover the largest possible inferior portion of the PTV 
with electrons. This meant the choice of electron energy required more than simply using the 
maximum depth of the PTV to select an energy with an adequate R90. Rather, the goal was to 
determine, for each energy being studied (13, 16, and 20 MeV), a superior border within the 
PTV, which defined the maximum volume that could be adequately covered with electrons 
alone.  
First, an initial electron aperture was generated for the entire PTV plus a margin of 1.5 
cm, as shown in Figure 2.3(a). Second, the plan was transferred to a flat top, cubical, water-
density phantom at 105 cm SSD for monitor unit (MU) determination in Pinnacle such that the 
CAX dose maximum (Dmax) was 55.6 Gy (i.e. 50 Gy/90%). Each energy specific MU was used 
to evaluate PTV coverage using a full field electron dose plan for each patient (full field, 
meaning the entire PTV was treated with only electrons). It should be noted that the Superflab 
was removed for all electron dose calculations for this project. Three energy specific superior 
loss-of-coverage locations, shown by example in Figure 2.3(b), were generated in the most 
inferior CT slice where a loss-of-coverage with 95% prescribed dose (47.5 Gy) occurred. In 
some instances, the position of a loss-of-coverage location could be moved superiorly through 
subsequent small changes in the electron beam gantry angle. An example of a final, nearly HBB 
electron field is shown in Figure 2.3(c). 
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2.1.4 X-ray beam Arrangement 
This section describes the methodology for selection of beam geometry parameters for 
the IMXT component of the BECT+IMXT or IM-BECT+IMXT planning technique. This 
consisted of two parallel opposed IMXT fields designed to spare lung, however to reduce a high 
esophagus dose compared to the other two patients, one patient required an additional IMXT 
field with more anterior incidence. IMXT dose optimization is described later in Section 2.3.5. 
2.1.4.1 RAO, LPO, and AP IMXT Gantry Angle Selection 
IMXT gantry angle selection started with the creation of the 6MV-RAO x-ray beam with 
a gantry angle of approximately 315°. CAX for this beam was directed at isocenter, which was 
placed initially midway through the patient, near the CAX of the electron beam, and at the 
superior edge (i.e. abutting side) of the electron beam as shown in Figure 2.4. A final gantry 
angle was determined by manually minimizing the lung and PTV overlap in the 6MV-RAO field 
BEV.  
Once a final gantry angle was selected for the 6MV-RAO field, a field edge matching 
algorithm implemented in MatLab vR2015b (The Mathworks Inc., Natick, MA) determined the 
remaining beam geometry. Using the algorithm, the MLC for this field was oriented such that its 
leaves traveled perpendicular to the plane of abutment. A description of the field-edge-matching- 
algorithm and its input/output parameters is given in Section 2.1.4.2.   
Once this remaining geometry was determined and input into Pinnacle for the 6MV-
RAO, the 10MV-LPO was generated using Pinnacle’s “copy and oppose beam” feature. The 
6MV-RAO and 10MV-LAO pair also had a medial HBB for the beam edges spanning the 
longitudinal patient axis.  Depending on the initial placement of the IMXT isocenter, alignment 
of the lateral HBB edge to the medial PTV border plus a 1 cm margin usually required small 
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adjustments of the final IMXT isocenter in the x- and y-plane. At final position, the HBB jaws 
produced a rectangle with 1 cm margin around all non-abutting sides of the combined γ-Target 
and JCT volume.   
For patient CW2, the additional (third) 6MV-AP field was added to the IMXT technique 
for esophagus sparing. This extra field was placed at a gantry angle of 350° and HBB inferiorly, 
but to keep the IMXT technique isocentric it did not have a medial HBB. The collimator for this 
field was oriented such that the MLC leaf travel was perpendicular to the length of overlapping 
Figure 2.4 Transverse plane, through the PTV (red) at the level of the field junction, showing 
a left anterior oblique (LAO) electron beam (yellow) directed a the electron isocenter 
labelled (1); and a right anterior oblique (RAO) x-ray beam (cyan) and left posterior oblique 
(LPO) x-ray beam (lavender) directed at the x-ray isocenter labelled (2). 
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esophagus. The 6MV-PA table and collimator angle were also determined using the field edge 
matching algorithm.   
2.1.4.2 Field Abutment  
 Gantry and table angles calculated from solutions to Siddon’s formulas as derived by 
Hernandez et al. (Hernandez 2009, Hernandez 2011), were used to geometrically match the 
rectangular x-ray beams to the superior electron beam edge with overlap (i.e. such that the 
electron and x-ray beam sides were parallel with the x-ray beams overlapping the electron beam 
by 1.5 cm). This overlap of the beam sides allowed for IMXT dose optimization over a 3 cm 
field junction region of the PTV (i.e. the JCT, defined in Section 2.1.5.2 as ±1.5 cm from the 
abutting electron beam edge) centered at the abutting electron beam side (i.e. 50% dose in the 
electron beam penumbra), as shown in Figure 2.5. A 3 cm span was selected as it encompassed 
the electron beam penumbra from 90-10% dose for a 10x 10 cm2, 16 MeV beam at a depth of 4 
cm. IMXT dose optimization using a uniform-dose optimization constraint (as described in 
section 2.3.5) for dose within the JCT effectively feathered the x-ray penumbra to compliment 
the broader electron beam penumbra. To this end, the field edge matching algorithm was also 
used to generate isocenter offset coordinates of non-optimized (open-field) HBB x-ray beams 
used solely for the purpose of bounding the JCT, i.e. PTV subtarget segmentation (Section  
2.1.5.1 and Section 2.1.5.2).  
 The field edge matching algorithm considered a plane of abutment to be parallel to the 
abutting electron beam side defined by a unit normal vector. The x-ray beam input parameters 
were an initial isocenter coordinate, gantry angle, and an abutment jaw setting (i.e. 0.0 cm for a 
HBB edge). These parameters only partially defined an abutting x-ray beam side because the 
table and collimator angles were unknowns. The electron beam input parameters were an 
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isocenter coordinate, gantry angle, collimator angle, a fixed 0° table angle, and an abutment 
electron block setting, defined by the distance from the CAX to the abutment edge of the 
electron block at or near  
the electron beam isocenter (i.e. 0.0 cm for HBB to typically within 5 cm for a nearly HBB 
electron field). These parameters completely defined the abutting electron beam side. 
 Using the unit normal vector for the plane of abutment, the algorithm first determined 
the collimator angle and table angle for an x-ray beam such that the beam sides would be parallel 
Figure 2.5 Sagittal CT plane showing a 3 cm JCT (green region) centered on the superior 
field abutment edge of a 13 MeV electron beam (yellow). The x-ray beam (red) overlaps the 
electron beam by 1.5 cm to allow for IMXT dose optimization on top of the electron dose in 
the penumbra region shown here by the 20% (brown), 30% (magenta), 50% (blue), 70% 
(green) and 80% (orange) isodose lines (IDL). 
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for the specified x-ray beam abutment jaw, electron beam abutting beam side (i.e. the block 
edge), and x-ray beam gantry angle settings. The algorithm then computed four sets of x-ray 
beam isocenter coordinates which were specific translations from the initially placed IMXT 
isocenter along the normal of the abutment plane.  
The four sets of isocenter coordinates offset HBB x-ray beam edges by 0.0 cm (i.e. the 
offset for non-overlap, non-gap abutment seen in Figure 2.6(a)), -0.5 cm, and ±1.5 cm from the 
Figure 2.6(a-c): (a) Non-overlapped field abutment, i.e. 0 cm offset x-ray beams for visual 
verification of field edge matching algorithm. The electron beam edge (blue line) and the x-
ray beam edge (yellow line) are coincident at the center of the 3 cm wide JCT (green region). 
(b) Field abutment with 1.5 cm offset x-ray beams for calculation of a gap 50% IDS used to 
segment the γ-Target (yellow region). (c) Field abutment with -1.5 cm offset x-ray beams for 
final treatment setup and calculation of an overlap 50% IDS used to segment the e-Target 
(blue region). 
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electron beam abutment edge. A positive 1.5 cm offset represented an abutment gap (Figure 
2.6(b)) between the parallel electron and x-ray beam sides and a negative 1.5 cm offset 
represented an overlapped abutment (Figure 2.6(c)). The x-ray beam isocenter coordinates for a 
negative 1.5 cm offset were the treatment isocenter for the IMXT arrangement. The 0.0 cm offset 
isocenter coordinate was solely used to position the HBB x-ray beam side coincident with the 
electron beam side for visual verification of the field edge matching algorithm results within 
Pinnacle’s 3D view. These isocenter shifts were also used to reposition the abutment x-ray field 
edges to generate intermediate (non-treatment) dose plans which were simply used during 
segmentation of the PTV into subtargets as described in Section 2.1.5.1 and Section 2.1.5.2, 
which describe the processes of generating regions of interest from 50% isodose surfaces for the 
intermediate dose plans.  
2.1.4.3 X-ray Jaw settings 
Each time an x-ray field isocenter was offset for treatment or PTV segmentation 
purposes, the jaws were also changed to maintain an abutment HBB or 1 cm margin around the 
non-abutting sides of PTV. This was accomplished by adding a block with a 1 cm PTV margin, 
setting the x-ray jaws to automatically encompass the block, and then setting the abutting jaw to 
0.0 cm. This process was done to ensure adequate γ-Target coverage with 1 cm PTV margin and 
to ensure that segmentation of the PTV was done using a non-divergent HBB x-ray field edge 
(i.e. in a plane parallel to the abutment plane). 
2.1.5 PTV subtarget segmentation 
Before beginning the segmentation process, it was first pertinent to undo the air density 
override of the Superflab bolus that was done during superior coverage estimations for the 
electron beams.  The process of segmenting the PTV utilized a 50% isodose surface (IDS) 
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generated from the dose plan of an un-modulated, open-field, x-ray beam. In the absence of 
specialized software tools capable of segmenting volumes with respect to beam sides, the 
abutment sides of these gap or overlap 50% IDS were used as approximations of planes parallel 
to and specific distances away from the field abutment edge of the electron beam. If the 
Superflab air density override was not removed for open-field x-ray beam dose calculation 
during the segmentation of the PTV, some small PTV volumes may have remained outside of the 
50% IDS due to dose build up at the patient surface. 
As seen in Figure 2.6(b), the Superflab bolus used during the simulation could be 
inadequate in covering the superior aspect of the γ-Target. On occasion, there were also air-gaps 
between the Superflab and the skin. Under these circumstances, a 1 cm thick bolus extension of 
the Superflab or an airgap override ROI was drawn in and given a density of 1.0 g·cm3. These 
additions to the Superflab bolus in the CT scan were also used during the planning process on the 
assumption that Superflab would be more adequately placed on the patient during a live 
treatment.  
2.1.5.1 Electron PTV (e-Target) and bolus design subtarget Definitions 
Segmentation of the PTV into an e-Target, as shown in Figure 2.6(c), in a plane parallel 
to the abutment edge of the electron beam was performed using the -1.5 cm x-ray isocenter offset 
and according overlap 50% IDS. The e-Target was defined as PTV less the overlap 50% IDS, 
yielding a uniform 1.5 cm electron field margin along its abutment side as shown in the diagram 
of Figure 2.7. The e-Target was solely used for plan evaluation purposes as a separate bolus 
design target, for use in p.d, was similarly segmented using the -0.5 cm isocenter offset and 
according overlap 50% IDS. The bolus design target has an intentionally reduced (0.5 cm) 
29 
 
electron field margin (i.e. an outer target margin, for bolus design) which allowed the BECT 
bolus to be designed 1 cm more superiorly within the electron field as seen in Figure 2.7.  
2.1.5.2 X-ray and Field Junction PTV Subtargets (γ-Target and JCT) 
 The γ-Target was segmented using the +1.5 cm x-ray isocenter offset and according gap 
IDS. The γ-Target was defined as the intersection of PTV and the gap 50% IDS, thus partitioning 
the γ-Target 1.5 cm superior to the abutting electron beam side. This target was used for IMXT 
dose optimization in the region of the x-ray beams unaffected by the field abutment. The JCT 
ROI was then defined as the PTV ROI less the union of e-Target and γ-Target ROI. This target 
was used during IMXT dose optimization in the region of the x-ray beams where dose 
inhomogeneity could arise because of the field abutment.  
2.1.6 Bolus Design  
Bolus design for the BECT and IM-BECT components was performed using sequences 
of bolus design operators as described by Low et al. (Low 1992), key ones which were available 
in the clinical version of p.d. An IM operator as described by Kudchadker et al.(Kudchadker 
Figure 2.7 Diagram of field abutment geometry showing JCT fully overlapped (3.0 cm) by 
the inferior photon field edge and partially overlapped (1.5 cm) by the superior electron field 
edge. The e-Target and bolus design Target have 1.5 and 0.5 cm field margins, respectively. 
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2002) was added to a research version of p.d for this project. Bolus design operators were 
applied in specific sequences to achieve a bolus design that met the planning goals. The planning 
goals for the BECT components in p.d (i.e. prior to composite plan renormalization in Pinnacle) 
were to circumscribe the e-Target with the 90% dose (100% = given dose) surface while limiting 
hotspots to 110% dose. The IM-BECT goals were to similarly circumscribe the e-Target, but 
with improved dose homogeneity. Dose calculation for the BECT and IM-BECT components, 
using p.d’s pencil beam redefinition algorithm (PBRA), was performed on a 2.5, 2.5, and 5 mm 
X, Y, and Z dose grid. In p.d, the PBRA calculated dose is displayed relative to a 100% 
reference dose equal to the given dose. Given dose is the maximum CAX dose given by a beam 
with perpendicular incidence to a water phantom, at the same CAX SSD as the wax bolus, and 
with the smallest rectangular field fully circumscribing the electron aperture (Kudchadker 2002). 
Electron beam information and required ROIs were transferred from Pinnacle to p.d in 
DICOM format. Electron beam information included: beam orientation (gantry, table, isocenter, 
etc.), block aperture, and electron energy. The required ROIs included: e-Target, ECT Skin, and 
Superflab. ECT Skin represented the exterior patient surface, which was used to design the distal 
bolus surface for proper fit with the patient. To prepare for designing a bolus a bolus density 
specification of 0.92 g·cm3 was set in the p.d linac configuration, as well as 13, 16, and 20 MeV 
broad beam 90% depths (R90) of 4.1, 5.1, and 6.0 cm, respectively. To accommodate the p.d 
bolus structure, the original CT images with a 50 x 50 cm2 field of view required padding to 70 x 
70 cm2. This was done by adding 20 cm left and anterior margins to each CT set. To remove the 
already-present Superflab bolus in the CT images, the lowest possible density override in p.d 
(0.01 g·cm3) was assigned to the Superflab ROI. This enabled proper patient surface detection by 
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the PBRA algorithm accurate dose calculation in cases where the wax bolus was designed with a 
thickness less than 1 cm. 
2.1.6.1  Description of Bolus Design Operators 
Bolus was designed using the p.d operators described below in Table 2.1.  
  
Operators used to design the bolus for ECT using p.d are based on a subset of the operators of 
Low et al. (1992) with some small changes. For more detail, refer to the p.d user manual. 
Construction and Extension Operators 
Creation Operator, Cp (,∆) 
Rt is a user specified therapeutic range (typically R90). ∆ is a user specified target inner margin, which is a distance, in the plane of the 
isocenter, between the edge of the target volume and the solid angle within which 
the initial bolus is designed. 
This operator creates an initial bolus surface. With respect to the source, the proximal 
patient skin surface defines the distal bolus surface. Cp only defines proximal bolus surface 
for ray-lines intersecting the target volume less target inner margin (TVLM) by bolus 
thickness ,	 along each (i,j) ray-line, where ,	 = ( − ,	) 
where: ,		is the distance from the proximal patient surface to the distal target surface along 
the (, 	) ray-line; 
Note: If ,	 < . 	, ,	 = . 	.  
The bolus surface is extended laterally using the height extension operator below. 
Height Extension Operator, Hh (∆,∆) ∆	is a user specified (1.0 cm in this work) block outer border margin, which is the 
distance, in the isocenter plane, between the inner edge of the custom electron 
collimator (block) and the unmilled region of the wax bolus (i.e. the block outer 
border). 
This operator extends bolus height on (i,j) ray-lines within the TVLM to the block outer 
border ∆. The extended bolus heights ,	 are defined separately for three zones (Low et 
al. 1992). In this work bolus heights in zone 1 were defined as the shorter of ,	 or the 
harmonic mean of (,	) and	(,	). Zones 2 and 3 are defined as per Low et al. 
where: 
 ,	 is the nearest neighbor of ,	 within the TVLM. (,	) is the nearest neighbor of ,	, where 	 = 	′. (,	) is the nearest neighbor of ,	, where  = ′. 
Note: The Height Extension Operator used in p.d was different from that defined by Low et 
al. This was corrected in a later release, after this project. 
 
  
Table 2.1 Description of p.d Bolus Design Operators 
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(Table 2.1 Description of p.d Bolus Design Operators continued) 
Modification Operators 
Isodose Shift Operator, I
 
(%D,∆) 
%D is a user definition of a distal percent dose surface ,	% specified as percent of 
given dose. (Typically, %D = 90%) 
Isodose Shift tries to match ,	% to a distal target surface ,		 !"# within ∆ by 
modifying bolus thickness ,	$% as	,	&#' = ,	$% + ,	% 	− ,		 !"#. 
Smoothing Operator, Gh (), *, +,) ) is a user specified exponential smoothing weight coefficient. * is a user specified smoothing region size factor. 
ps is a user specified point-spacing (0.1, 0.2, or 0.4 cm) defining a bolus surface mesh.  
This operator modifies the proximal bolus surface by smoothing bolus height on each (, 	) 
ray-line by ,	,$$(), *, +,) = 	∑ [,	#
/)! 0 ,	 12 ]* ,	
∑ [#/)! 0 ,	 12 ]* ,	
 
where: 
 ,	,$$is the smoothed bolus height on each (, 	) ray-line.  ,	 is point spacing ps projected along each (, 	) ray-line to the distal target surface. 
Note: Gh as used in p.d was different from that defined by Low et al. (i.e.  ,	 is not 
the 2nd scattering moment specified by Low et al.) ,	 is unsmoothed bolus height along (4, 	′) ray-lines within the region * . 
r is the distance from an	(, 	) ray-line to an	(4, 	′) ray-line, where r ≤ * . 
Specified Shift Operator, S
 
(δ,∆) 
         δ is a specified shift of the milled bolus surface within the block outer border ∆. 
This operator shifts the entire proximal bolus surface toward the beam source by δ, 
effectively changing the bolus thickness along each (i,j) ray-line to ,	 = ,	 +	δ. A 
negative value of δ shifts the entire proximal bolus surface inside the block outer border 
away from the beam source, shifting isodose lines (IDL) deeper into the patient. 
Truncation Operator, T
 
(∆) 
This operator only modifies the proximal bolus surface outside the block outer border ∆ 
by truncating bolus height ,	 on each (i,j) ray to (,	) . 
where: (,	)  is the maximum bolus surface height within the block outer border. 
Modulate Intensity Operator, M
 
(∆, ' ) 
This operator modifies weights wi,j of each PBRA pencil beam intersecting the TVLM, i.e. 
within ∆, as ',	&#' = &[' , ',	$% ∙ 6%  (,	)⁄ 	]. Presently, the 1st 
application of M in p.d uses ',	$% = ',	& % = 6.  . 
where: 89:(,	) is the maximum dose along each (i,j) ray-line. '  is the un-normalized maximum pencil beam weight (1.1 in this work). 
Outside the TVLM, IM weights are extended according to Low et al. 
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2.1.6.2 Application of Bolus Design Operators 
The sequences in which p.d operators were applied are given below in Table 2.2.  
Table 2.2 Summary of Bolus Design Operator Sequences 
 
2.1.6.3 Basis for Bolus Design Methodology 
The distal surface of the bolus design target, the target volume ROI specified in p.d, was 
used to modify bolus height within a target inner margin, ∆I. The target inner margin provides 
the bounds of the physical depth creation operator, Cp,, a bolus construction operator, and two 
other bolus modification operators including isodose shift, I, and specified shift, S. Prior to the 
application of bolus operators, a standard 2 mm (i, j) point spacing was selected in p.d (i.e. ps = 2 
mm), which defined the bolus along ray-lines from the source. The 2 mm point spacing and the 
target inner margin are specified at the isocenter plane, 100 cm from the source according to 
Low et al. (Low 1992).  A 1 cm block outer border, ∆O, was also specified in this plane, which 
restricted bolus height extension outside of the target volume less inner margin (TVLM) to 
within 1cm beyond the electron block.  
Step 13/16 [MeV] BECT 20 MeV BECT 13/16 [MeV] IM-BECT 20 MeV IM-BECT 
1.
 
Cp[90%, 0.5 cm] Cp[85%, 0.5 cm] Cp[90%, 0.5 cm] Cp[85%, 0.5 cm] 
2.
 
Gh[1, 10, 0.2 cm] Gh[1, 10, 0.2 cm] Gh[1, 10, 0.2 cm] Gh[1, 10, 0.2 cm] 
3. I[90%, 0.5 cm] I[85%, 0.5 cm] I[90%, 0.5 cm] T[1.0 cm] 
4.
 
Gh[1, 10, 0.2 cm] Gh[1, 10, 0.2 cm] Gh[1, 10, 0.2 cm] S[-7 mm, 1.0 cm] 
5.  I[90%, 0.5 cm] T[1.0 cm] I[90%, 0.5 cm] M[0.5 cm, 1.1] 
6. Gh[1, 10, 0.2 cm] S[-7 mm, 1.0 cm] Gh[1, 10, 0.2 cm] I[90%, 0.5 cm] 
7. T[1.0 cm]  T[1.0 cm] Gh[1, 10, 0.2 cm] 
8. S[-2.5 mm, 1.0 cm]  S[-2.5 mm, 1.0 cm] S[-7 mm, 1.0 cm] 
9.   M[0.5 cm, 1.1] M[0.5 cm, 1.1] 
10.   I[90%, 0.5 cm] M[0.5 cm, 1.1] 
11.   Gh[1, 10, 0.2 cm]  
12.   S[-2.5 mm, 1.0 cm]  
13.   M[0.5 cm, 1.1]  
14.   M[0.5 cm, 1.1]  
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2.1.6.4 BECT: Bolus Design Sequence  
For a given selected electron beam energy, Cp computed bolus thicknesses, b(i,j), along 
ray-lines within the TVLM as the difference between the physical distal target depth, d(i,j), and a 
selected therapeutic range, Rt, (typically R90%). Following Cp, the bolus height extension 
operator, Hh, automatically extended the distal (upstream) bolus surface within the TVLM to ray 
lines a distance ∆O beyond the electron aperture.  Hh was performed by extending three sets of 
bolus heights, H(i',j’), defined for three zones (Low et al. 1992). In this work, bolus heights in the 
inner zone 1 were defined as the shorter of the nearest neighbor, h(i,j), or the harmonic mean of 
h(i,j)x and h(i,j)y. Outer zones 2 and 3 were based on Low et al. (Low 1992). 
Since the PTV ROI was not distally smooth, Cp could produce bolus height irregularities. 
These irregularities combined with electron multiple Coulomb scattering (MCS), could generate 
hot and cold regions in the PTV. To remove proximal bolus surface irregularities, an application 
of the Gaussian height smoothing operator, Gh, modified the b(i,j) bolus heights with weighted 
averages of neighboring bolus heights enveloped by a smoothing region size factor, η, and 
exponentially weighted by a smoothing weight factor, µ. 
 The I operator was then applied to modify each b(i,j) height within the TVLM by the 
difference between d(i,j) and the depth of a percent given dose IDS, between 85-90%, specified to 
circumscribe the PTV. The I operator was is a one dimensional operator, meaning it only the 
considered the difference between d(i,j) and the depth of the percent given dose IDS along the 
same (i,j) ray line. Since electrons scatter, the I operator typically required more than one 
application for ideal PTV conformity. However, for barrel-chested anatomy, iterative 
applications of the I operator could also lead to high bolus surface gradients, and therefore 
shallow hotspots due to MCS.  
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Application of the smoothing operator, Gh, resulted in a smoother proximal bolus surface 
and reduced hotspots formed by MCS. Therefore, Gh was always performed before and after 
isodose shift to strike a balance between necessary high surfaces gradients, as in the case of a 
barrel-chested anatomy, and surface irregularities resulting from the use of the I operator with an 
irregular distal PTV surface. In the latter case, Gh sometimes compromised distal target coverage 
where the distal target shape was highly irregular; and in the former case, Gh could smooth out 
the sloped surface required to achieve ideal distal coverage. This combination of surface 
irregularities and surface slope existed due to jagged PTV contouring and the concavity of the 
distal CW region of the PMRT PTV. The strong smoothing settings (large η and low µ) required 
to deal with the surface irregularities arising from jagged PTV contouring also led to an over 
smoothed slope that reduced distal coverage. 
Because of the reduced coverage, the specified shift operator (S) was applied to 
uniformly shift the 87% given dose (95% prescribed dose) isodose surface to a final deeper depth 
improving PTV coverage. Bolus height modification with S [δ = -2.5 mm] accomplished this 
based on a visual inspection of dose, the sole dosimetric analysis tool in p.d.  
Finally, the bolus height outside of the electron block plus the margin ∆O was uniformly 
reduced with the truncation operator, T. Truncation reduced unnecessary size and weight of the 
wax bolus by designing the un-modulated bolus height to be 5 mm above the largest bolus 
height. Table 2.2 provides a summary of the bolus design operators. 
The entire BECT operator sequence for 13 and 16 MeV was a double isodose shift, 
followed by a -2.5 mm specified shift. Using a double isodose shift sequence at 20 MeV 
produced oscillations in the bolus surface which led to unacceptable oscillations in the distal 
90% IDS and hot spots as shown in the upper isodose plot of Figure 2.8. It is believed that a 
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combination of PBRA noise in the 90% IDS and reduced electron scattering (less smoothing of 
the noise) at 20 MeV, was responsible for this.  
Therefore, a single isodose shift sequence using the 85% IDS was applied, which yielded 
better results as shown in shown in the lower isodose plot of Figure 2.8. This single shift 
sequence was followed by a -7 mm specified shift, which was composed of ½ of (R90 – R80) for 
20 MeV (-4.5 mm) plus the normally applied -2.5 mm specified shift. The p.d double shift 
sequence in its automated order consists of Cp, Gh, I, Gh, I, Gh and T. The automated single shift 
sequence has one less repetition of I and Gh. For 13/16 and 20 MeV beams the full sequences are 
shown in Table 2.2. 
2.1.6.5 IM-BECT: Bolus Design (with Intensity Modulation) Sequence 
The intensity modulation algorithm and p.d operator were implemented into p.d by 
professionals with PBRA expertise. M determined intensity factors as 100% divided by the 
maximum relative dose for each ray-line. Intensity modulation factors were only determined 
within the TVLM, but an intensity factor extension operator was automatically invoked to extend 
intensities from the TVLM to the edge of the field. All factors were stored in a target map.  
The IM-BECT sequence is similar the BECT sequence, but care had to be taken in 
ordering the intensity modulation operator (M) within the sequence. Upon the first application of 
M, the target map was multiplied by the initial applied map containing factors of unity to 
produce a new applied map. Before dose recalculation, the applied map factors were restricted 
within the range of 0.8 – 1.1.  Subsequent applications of M repeated this process.   
Care was taken with ordering M in the operator sequence, not applying it too early.  
Better results were found by using it after at least one isodose shift and smoothing operation 
instead. Earlier use could lead to oscillations in the distal 90% IDS which then led to surface  
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irregularities following subsequent isodose shifts. The IM-BECT operator sequence used for 13 
and 16 MeV appended M, I, Gh, S, M, and M to the end of the BECT double shift operator 
Figure 2.8(Top) Isodose plot of unacceptable p.d BECT dose at 20 MeV resulting from the 
use of a double shift sequence with %D = 90%. (Bottom) Isodose plot of improved p.d 
BECT dose at 20 MeV resulting from the use of a single shift sequence and %D = 85%. IDL 
are 102% (red), 98% (yellow), 90% (green), and 87% (white). Specified shift of -7.0 mm not 
applied in these images. 
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sequence. However, at 20 MeV intensity modulation improved the performance of an initial 
isodose shift operation because often there were areas of neighboring ray-lines with less than 
90% dose maximum, which were due to large variations in bolus SSD resulting in areas of 
reduced side scatter. Hence, M was applied in the sequence prior to the first I. The 20 MeV IM-
BECT operator sequence began with a single geometric shift sequence (Cp, Gh, T), which only 
performs a creation (using Rt= R85%), smoothing, and truncation. This was followed by a -7 mm 
specified shift. Next intensity modulation was applied once before and twice after a subsequent 
isodose shift and smoothing. Last a specified shift of -7 mm as shown in Table 2.2.  
2.1.6.6 Export of relative dose from p.d and determination of absolute dose 
After the final BECT and IM-BECT dose distributions were computed with the PBRA in 
p.d, they were exported as relative per monitor unit via a DICOM dose export. Because Pinnacle 
does not support DICOM dose import, an in-house software converted the p.d relative dose per 
MU stored in the DICOM file to absolute dose per MU in Pinnacle compatible file format. In 
Pinnacle, an initial, MU setting for the electron beam was determined using the MBPCCC 
Electron MU calculation program. Final electron beam MU were specified by the composite plan 
normalization process, Section 2.1.8 
2.1.7 IMXT Optimization 
All ROI used for IMXT dose optimization are defined below in Table 2.3. Parallel 
opposed intensity modulated x-ray beams served three purposes in the PMRT planning strategy: 
1) to improve dosimetry in the JCT ROI where the electron and x-ray fields were abutted, 2) to 
improve the γ-Target and normal tissue (NT) dosimetry for the parallel opposed beam 
arrangement used within a region of varying patient thickness, and 3) to minimize dose to OAR.  
Inverse plan optimization and dose calculation was performed in Pinnacle using the direct 
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machine parameter optimization (DMPO) algorithm and the adaptive convolve dose engine 
respectively. The IMXT beams were optimized on top of the BECT and IM-BECT dose 
distributions imported from p.d. using a uniform 2 mm dose grid.  
The third purpose is one of the major advantages of IMXT techniques, but for parallel 
opposed beams arrangements it was not very practical given the inherent restriction on the 
number of IMXT beams (i.e. 2). Thus, the ipsilateral lung constraints used with the two-field 
parallel opposed IMXT arrangement were given low (i.e. ≤ 15) objective weights. For the three 
field IMXT arrangement, for which a 6MV-AP field was added over the ipsilateral lung for 
esophagus sparing, ipsilateral lung and esophagus objective weights were set to 30 and 90, 
respectively.  
The first and second purposes required γ-Target, JCT, and two additional ROI: NT 
Avoidance and JXN-NT Avoidance. NT Avoidance was used minimize hotspots in TN in CT 
slices containing the γ-Target. The JCT-NT Avoidance ROI was used to minimize hotspots 
within the JCT plus NT within CT slices containing the JCT. The γ-Target was given minimum 
and maximum dose constraints, as well as a minimum DVH constraint, while the JCT was given 
 
ROI Definition 
JCT The volume of PTV Evaluate within 1.5 cm inferior of 1.5 cm superior of the superior electron beam edge. 
γ-Target The remaining PTV Evaluate volume treated with IMXT. 
NT Avoidance Normal Tissue (NT) within CT slices containing the γ-Target less a 1 cm 
expansion of the γ-Target. 
JCT-NT 
Avoidance JCT plus NT within CT slices containing the JCT. 
Ipsilateral Lung Physician contoured left lung volume. 
Esophagus Physician contoured esophagus volume.  
Cold Region Small volume of low dose (<30 Gy), within medial γ-Target, delineated following initial IMXT dose optimization.  
 
Table 2.3 Definitions of ROI used for IMXT dose optimization 
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Table 2.4 IMXT Dose-volume objective 
ROI Type Dose [cGy] Volume [%] Weight 
NT Avoidance Max Dose 5250 - 90 
JXN-NT Avoidance Max Dose 5250 - 90 
Ipsilateral Lung Max DVH 3000 20 15 
Ipsilateral Lung Max DVH 2000 30 5 
Ipsilateral Lung Max DVH 1000 40 5 
Ipsilateral Lung* Max DVH 3000 20 30 
Ipsilateral Lung* Max DVH 2000 30 30 
Ipsilateral Lung* Max DVH 1000 40 10 
Esophagus* Max DVH 500 5 90 
JCT Min DVH 4950 95 90 
JCT Uniform Dose 5000 - 100 
γ-Target Min DVH 4750 95 100 
γ-Target Max Dose 5250 - 100 
γ-Target Min Dose 5000 - 90 
Cold Region Min Dose 4000 - 100 
 
For the three-field technique, Ipsilateral Lung* objectives were substituted for Ipsilateral 
Lung objectives and Esophagus* was added to the objective list. 
a uniform dose and a minimum DVH constraint. Following an initial IMXT dose optimization, 
the minimum dose within the γ-Target was improved by setting an additional minimum dose 
constraint for the Cold Region, a volume within the γ-Target which was delineated as the γ-
Target less volume receiving less than 30 Gy. The Cold Region was typically close the medial 
IMXT penumbra where the patient surface separation was larger than on the lateral side.  
Table 2.4 lists the ROIs given an objective type and the objective dose-volume constraint 
and weight. The changes made to objectives of the two-field technique to optimize dose for the 
three-field technique are represented by asterisks. These were determined to satisfactorily meet 
optimization needs and thus were not altered between patients. The x-ray beam jaw settings 
defined in Section 2.1.4.2 were set to be the maximum allowable in the optimizer settings 
preventing e-Target IMXT exposure.  
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2.1.8 Composite Plan Normalization 
Composite plan normalization was carried out during a two-step IMXT optimization 
process. The first step was to adjust electron beam weight such that a mean dose of 
approximately 50 Gy was given to the electron target (e.g. for the e-Target, Dmean ≈ 50 Gy). Then 
IMXT dose was optimized on top of the electron dose by running the optimization a maximum 
of 70 iterations with 40 convolution dose iterations followed by addition of the Cold Region 
constraints. Afterward, the final electron beam weight (MU) was adjusted such that for the 
composite plan, 95% relative volume of PTV received 95% of the 50 Gy prescription dose (i.e. 
for PTV, V95% (47.5Gy) = 95%). The second step was to “warm-start” the IMXT optimization and if 
necessary afterward, adjust final photon beam weight such that for PTV, V95% = 95%.   
2.1.9 Electron Energy Comparison Study 
The goal of the energy study was to compare the differences in PTV, heart, and lung dose 
for three electron beam energies and their respective field sizes. It was hypothesized that the 
treated lung volume from both electron and x-ray beams would decrease with increased electron 
beam energy. The basis for this hypothesis was the increased PTV depth superiorly and the need 
to treat any PTV region too deep for coverage with electrons with more penetrating IMXT fields. 
Since the IMXT(3fld) plan adds a third x-ray beam over the lung, the energy study results only 
include comparisons of the BECT-IMXT(2fld) plans. 
2.1.9.1 Analysis of Extent of Superior Coverage 
For all three patients, increased superior coverage was analyzed by visual BEV 
inspection. Gains in electron field size in the superior direction were compared, first 16 MeV 
with respect to 13 MeV, then 20 MeV with respect to 16 MeV.  Overall coverage gain was 
estimated by the minimum and maximum gain for all three patients.  
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2.1.9.2 Analysis of PTV, Lung, and Heart DVH 
For all three patients, DVH comparisons BECT+IMXT plans at 13, 16, and 20 MeV were 
performed with visual inspection of the DVH and extraction of PTV V95(47.5Gy), lung V20Gy, and 
heart V30Gy from DVH data. Similar comparisons were also performed for each IM-
BECT+IMXT plan. If it was determined that there was not a benefit to PTV coverage or lung 
sparing with the use of more superior covering, higher energy electron beams, then only the 
lowest electron energy plans meeting the PTV D95% ≥ 47.5 Gy criteria were considered for 
potential clinical acceptability. Although, if these benefits were found, the expected increase in 
the heart V30Gy with electron beam energy would need to be considered before using any 
energy higher that what is necessary to achieve PTV coverage superior to the heart with BECT 
or IM-BECT.  
 
  
2.1.9.3 Analysis of Effect of Intensity Modulation for each Energy 
Analysis of the effect of intensity modulation on dose homogeneity was performed for 
each energy using the dDVH for the e-Target of a single patient, CW2. The FWHM of the 
BECT+IMXT e-Target dDVH was compared to the FWHM of the IM-BECT+IMXT e-Target 
dDVH. For 16 and 20 MeV the dDVH for the e-Target ROI, as segmented for the 13 MeV plan, 
were compared since it was the only single ROI covered by all electron energy fields. Following 
the intensity modulation effect comparison for all energies with one patient, similar comparisons 
were made for all three patients using only the planning energy selected for potential clinical 
acceptability.    
2.1.10 Plan Review and Documentation 
 Potential clinical acceptability of left-side PMRT plans was standardized such that at 
least 95% volume of the PTV received 95% prescribed dose while limiting lung V20Gy ≤ 20% and 
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heart mean dose to less than 8 Gy.  For each reviewed plan, the electron field BEV and the x-ray 
field BEV are shown to depict target coverage and/or OAR overlap. The electron field BEV 
include a surface display of the e-Target, JXN, and γ-Target. X-ray BEV included a wire-frame 
display of these, as well as lung, heart, and esophagus. For the IM-BECT+IMXT plans an 
intensity modulation map is shown with the electron BEV. The following sections describe the 
order of plan review and documentation. 
2.1.10.1 Plots of BECT and IM-BECT Isodose Lines 
Plots of Isodose lines (IDL) for potentially clinically acceptable BECT+IMXT and IM-
BECT+IMXT plans were reviewed and documented in transverse planes in three specific CT 
slices, in which the dose distribution primarily varied because of the applied treatment technique. 
These CT slices include transverse planes through the e-Target treated with BECT and IM-
BECT, the JCT treated with the former overlapped with IMXT, and the γ-Target treated with 
IMXT. A fourth view in one sagittal plane through the heart was also reviewed and documented.  
2.1.10.2 BECT DVH Analysis 
The DVH of each OAR and the PTV were reviewed and documented for potential 
clinical acceptability of BECT+IMXT and IM-BECT+IMXT plans. Dose metrics were then 
extracted from the DVH and the specific PMRT metrics mentioned above for PTV, heart, and 
lung were used to test potential clinical acceptability.  
2.1.10.3 Dose Metrics 
In addition to the dose metrics used to test for clinical acceptability of the plans other 
common metrics were also extracted from the DVH data and documented. The complete set of 
reported values include the following PTV, heart, and lung DVH metrics: 
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i. Dose metrics reported for PTV: 
• PTV- Dmin, Dmax, Dmean, and standard deviation (SD)  
 
• PTV-V95, the relative PTV volume receiving 95% of the 50 Gy prescribed 
dose (V47.5Gy/VPTV) 
 
ii. Heart dose metrics: 
• Heart- Dmin, Dmax, Dmean, and SD 
 
• Heart-V30Gy, the relative heart volume receiving 30 Gy (V30Gy/Vheart) 
 
 
iii. Lung dose metrics: 
• Lung- Dmin, Dmax, Dmean, and SD 
 
• Lung V20Gy, the relative lung volume receiving 20 Gy (V20Gy/Vlung) 
 
 
2.2 Results 
 
For CW2, CW3, and CW6, each patient had six different composite plans; BECT+IMXT 
and IM-BECT+IMXT plans: BECT+IMXT(2fld) at 13, 16, and 20 MeV and IM-
BECT+IMXT(2fld) at 13, 16, and 20 MeV. A high esophagus dose was a result of the 
application of the IMXT(2fld) component for CW2; therefore, for this patient, 
BECT+IMXT(3fld) and IM-BECT+IMXT(3fld) were also planned.  
2.2.1 Electron Energy Comparison Study 
 All results from the energy study pertain only to BECT+IMXT(2fld) or IM-ECT+IMXT 
(2fld) plans. 
2.2.1.1 Superior Coverage Analysis 
Figure 2.9, shows the differences in superior PTV coverage using various different 
electron beam energies for CW2, CW3, and CW6. Measuring from the inferior electron field 
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edge it was seen that 1-2 cm more superior coverage was possible for 16 MeV compared to 13 
MeV, and an additional 2-3 cm gain in superior coverage was possible using 20 MeV.  These 
gains in coverage however, did not result in a reduction in treated lung volume for the composite 
16 and 20 MeV plans where the increase in electron energy and range had greater effect on 
Figure 2.9 BEV of CW2 (top row), CW3 (middle row), and CW6 (bottom row) electron 
fields (red) for 13 MeV (left), 16 MeV (middle), and 20 MeV (right) showing increased 
superior coverage of the PTV with increased electron beam energy. PTV is shown in green. 
Positive gains were measured with respect to 13 MeV references. 
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treated lung volume than the reduction of inferior x-ray field coverage (more detail in results 
section 2.2.1.2). In other words, there was no lung benefit from a reduction in x-ray field size in 
the inferior direction, with increased electron field size in the superior direction, if satisfactory 
distal PTV coverage required increasing electron energy from 13 MeV to 16 or 20 MeV.  
2.2.1.2 BECT and IM-BECT Composite DVH for PTV, Lung, and Heart  
The DVHs for BECT+IMXT and IM-BECT+IMXT plans at 13, 16, and 20 MEV are 
shown for CW2, CW3, and CW6 in Figure 2.10, Figure 2.11, and Figure 2.12, respectively. Each 
13, 16, and 20 MeV BECT+IMXT and IM-BECT+IMXT plan generated for CW2, CW3, and 
CW4 were considered to have met the PTV V95(47.5Gy) ≥ 95% criteria from inspection of the 
DVH, although some V95 were in the range of 94.7 to 95.6% because of the plan normalization 
method for BECT/IM-BECT+IMXT composite Plans. None of the three patient cases had plans 
that yielded lung sparing with increased electron beam energy and correspondingly increased 
superior PTV coverage. A slight crossing of the lung DVH for 13, 16, and 20 MeV was noted in 
both BECT+IMXT and IM-BECT+IMXT plans for all patients at doses between 40-45 Gy, 
which did not occur for the heart DVH. As shown in Table 2.5, the lung V20Gy < 20% criteria 
was achieved for each patient’s 13 MeV plans (i.e. with and without IM-BECT), for each 16 
MeV CW2 plan, and exceeded by all other 16 and 20 MeV plans.  The heart V30Gy was increased 
approximately 10% with the use of 20 MeV compared to 13 MeV. The overall finding was that 
while all three electron beam energies allowed for PTV V95(47.5Gy) to be within 94.7-95.6%, the 
lower energy BECT components always resulted in lower treated volumes of heart and lung 
despite increased PTV and lung overlap in the corresponding IMXT fields.  
The three different electron energies: 13, 16, and 20 MeV were selected from those 
available for clinical use at Mary Bird Perkins. Electron energy DVH comparisons for CW2,  
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Figure 2.10 CW2 DVHs for 13, 16, and 20 MeV (represented as thin, medium, and heavy 
weight lines, respectively) BECT+IMXT plans (top) and IM-BECT+IMXT plans (bottom) 
showing PTV (green), lung (blue), and heart (pink). Lung V20 < 20 Gy for both 13 MeV and 
16 MeV plans. Heart V30Gy increased approximately 10% for 20 MeV plans compared to 13 
MeV plans. 
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Figure 2.11 CW3 DVHs for 13, 16, and 20 MeV (represented as thin, medium, and heavy 
weight lines, respectively) BECT+IMXT plans (top) and IM-BECT+IMXT plans (bottom) 
showing PTV (green), lung (blue), and heart (pink). Lung V20 < 20 Gy for both 13 MeV 
plans. Heart V30Gy increased approximately 10% for 20 MeV plans compared to 13 MeV 
plans. 
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Figure 2.12 CW6 DVHs for 13, 16, and 20 MeV (represented as thin, medium, and heavy 
weight lines, respectively) BECT+IMXT plans (top) and IM-BECT+IMXT plans (bottom) 
showing PTV (green), lung (blue), and heart (pink). Lung V20 < 20 Gy for both 13 MeV 
plans. Heart V30Gy increased approximately 10% for 20 MeV plans compared to 13 MeV 
plans 
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CW3, and CW6, in Figure 2.10, Figure 2.11, Figure 2.12, respectively show significant 
reductions in treated lung and heart with 13 MeV compared to 16 MeV and likewise for 16 MeV 
compared to 20 MeV. This suggests that for BECT+IMXT and IM-BECT+IMXT 
postmastectomy chest wall treatments, a therapy linac with smaller electron energy spacings 
would allow for less compromise on heart and lung sparing when increased electron energy is 
required. Table 2.5 shows the increase in Lung-V20Gy and Heart-V30Gy with clinically available 
energies.   
Table 2.5 PTV-V95, Lung-V20Gy, and Heart-V30Gy for CW2, CW3, and CW6 
BECT+IMXT and IM-BECT+IMXT plans at 13, 16, and 20 MeV 
CW2 PTV-V95 [%]  Lung-V20Gy [%] Heart-V30Gy [%] 
13 MeV 94.9 14 0.2 
16 MeV 94.7 16.1 1.0 
20 MeV 95.2 25.2 10.1 
CW2-IM PTV-V95 [%]  Lung-V20Gy [%] Heart-V30Gy [%] 
13 MeV 95.1 13.8 0.2 
16 MeV 95.0 16.2 1.6 
20 MeV 95.5 24.1 9.4 
CW3 PTV-V95 [%]  Lung-V20Gy [%] Heart-V30Gy [%] 
13 MeV 95.0 19.6 1.2 
16 MeV 95.0 24.9 3.0 
20 MeV 95.0 34 11.4 
CW3-IM PTV-V95 [%]  Lung-V20Gy [%] Heart-V30Gy [%] 
13 MeV 95.0 18.6 0.3 
16 MeV 95.0 23.6 2.2 
20 MeV 95.0 31.2 8.3 
CW6 PTV-V95 [%]  Lung-V20Gy [%] Heart-V30Gy [%] 
13 MeV 94.7 18.1 3.4 
16 MeV 95.0 22.5 6.5 
20 MeV 95.5 32.8 16.3 
CW6-IM PTV-V95 [%]  Lung-V20Gy [%] Heart-V30Gy [%] 
13 MeV 94.8 17.8 2.2 
16 MeV 95.6 21.9 5.2 
20 MeV 94.7 30.2 12.8 
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2.2.1.3 Effect of Intensity Modulation for each Energy 
Intensity modulation of the electron beams was investigated for the potential to improve 
PTV dose homogeneity for all electron energies tested in the energy comparison. However, 
higher energy 16 and 20 MeV plans were found to be inferior to 13 MeV plans in terms of larger 
lung V20Gy and heart V30Gy, thus only CW2 BECT+IMXT and IM-BECT+IMXT plan 
comparisons are presented for all three energies, and plan comparisons for CW3 and CW6 have 
been limited to 13 MeV. In Figure 2.13, pairs of dDVH are shown for the BECT+IMXT and IM-
BECT+IMXT plans at 13, 16, and 20 MeV created for CW2. The plotted dDVH of each pair is 
the e-Target as segmented for 13 MeV. This ROI is the only single target that was fully covered 
by the field size of each energy electron beam, and it was used to remove differences in the 
compared dDVH arising from the differences in the dose distribution in more superior regions of 
the PTV, in attempt to isolate differences due to electron energy.  
 For 13 and 16 MeV distributions shown in Figure 2.13, the FWHM for the IM-
BECT+IMXT plans are reduced compared to the BECT+IMXT plans which is an indication of 
increased dose homogeneity within the e-Target. For the 20 MeV distributions however, the IM 
operator that was used resulted in a larger FWHM. This is believed to be due the combination of 
less rapid dose distal falloff at 20 MeV and the PBRA pencil beam multiplier, which did not 
account for whether dose maximums along each ray line were within the bolus or PTV. For all 
energies, there was a sharper dose falloff in the volume on the high dose side of the IM-
BECT+IMXT distribution compared to the high dose side of the BECT+IMXT distribution. The 
dose at which the IM-BECT+IMXT volume falloff occurs on the high dose side is highest for 20 
MeV.  The peak volumes for IM-BECT+IMXT distributions were located at doses near the 
peaks in BECT+IMXT distributions except for 20 MeV. It was also observed that the  
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BECT+IMXT distribution for 20 MeV shows a peak below the 50 Gy prescription dose. This is 
believed to be due the combination of plan normalization criteria that V95(47.5Gy) = 95% and less 
rapid dose distal dose falloff at 20 MeV. 
The dDVH for the 13 MeV e-Target for 13 MeV BECT+IMXT and IM-BECT+IMXT 
plans for CW2, compared to CW3 and CW6 are shown in Figure 2.14.  For each IM-
BECT+IMXT distribution in Figure 2.14, the dDVHs FWHM is reduced and there is a sharper 
volume falloff on the high dose side compared to the BECT+IMXT plan. The peaks of IM-
BECT+IMXT occur at the same doses as the peaks of IM-BECT+IMXT plans, except for CW3.  
Figure 2.13 CW2 13 MeV e-Target dDVH for BECT+IMXT(solid lines) and IM-
BECT+IMXT (dashed lines) plans at 13, 16, and 20 MeV. FWHM are reduced with the use 
of intensity modulation with exception of 20 MeV.  
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Figure 2.13 and Figure 2.14 include tables of the FWHM of 13 MeV e-Target dDVH for 
each plan as indicators of the dose spread within the electron PTV subtarget. For the 13 MeV and 
16 MeV BECT+IMXT and IM-BECT+IMXT plans for CW2 there were 1.2 Gy and 2.4 Gy 
reductions in FWHM, respectively, when intensity modulation was used. For 20 MeV CW2 IM-
BECT+IMXT and BECT+IMXT plans however, there was a 1.6 Gy increase in FWHM with the 
use of intensity modulation. In the 13 MeV BECT+IMXT and IM-BECT+IMXT plans for CW3  
  
Figure 2.14 CW2, CW3, and CW6 e-Target dDVHs for 13 MeV BECT+IMXT plans (solid 
lines) compared to 13 MeV IM-BECT+IMXT plans (dashed lines). All IM-BECT+IMXT 
distributions show reduced FWHM. Compared to the FWHM, the SD of dose within the e-
Target shows mixed results: 13 MeV IM-BECT decreased SD for CW3 and increased SD 
forCW6. 
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and CW6 there were also FWHM reductions with the use of intensity modulation, as found with 
CW2, that amounted to 1.4 Gy and 2.2 Gy, respectively.  
2.2.2 Dose and DVH Examination of 13 MeV Potentially Clinically Acceptable Plans 
For the two-field IMXT technique, minimal differences were observed between patients 
in terms of isodose distributions. For this reason, isodose plots and DVH will only be shown for 
the CW2 two-field and three-field plans. Isodose plots and DVH for CW2, CW3, CW6, and 
other patients planned in Aim 2 (CW3,4, & 7-9) are shown in Appendix A. 
2.2.2.1  13 MeV BECT+IMXT(2fld) and IM-BECT+IMXT(2fld) 
The plans reviewed below were created with 13 MeV BECT+IMXT(2fld) and IM-
BECT+IMXT(2fld) techniques. They have all been determined to be clinically acceptable based 
on the requirements defined in section 2.1.10. The review format is as follows:  1) BEV, 2) 
isodose plots for each technique, 3) DVH comparing both techniques, and 4) dose-volume 
metrics. 
i. Review of 13 MeV CW2 plans using the IMXT(2fld) component 
 
For CW2, the upper left and right BEV in Figure 2.15 depict the 6MV-RAO and 10MV-
LPO IMXT fields, respectively. In the x-ray BEV there is γ-Target, JCT, esophagus, and lung 
overlap while the heart and cord are completely outside the fields. The lower right and left BEV 
depict the intensity modulation map for the 13 MeV IM-BECT field and the electron field 
aperture for both the BECT and IM-BECT fields, respectively. Figure 2.15 also includes an 
intensity modulation color legend, which shows the intensity modulation factors in the intensity 
modulation map were as high as 1.1 in accordance with the maximum allowed by the intensity 
modulation operator in p.d. Within the intensity modulated electron field there is generally more 
red area of increased intensity with localized blue zones of decreased intensity near the medial 
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and lateral sides of the PTV. The red regions of the intensity modulation map are for ray-lines 
which received less MCS or were at increased SSD because of the rounded bolus surface, 
resulting in less than 100% given dose along those ray-lines. The blue regions of decreased 
intensity are for ray-lines which received more MCS because of the bolus surface inflections, 
which led to hotspots along those ray-lines. The minimum intensity modulation factor was 0.845.   
Figure 2.15 CW2-13 MeV BEV: 6MV-RAO field (top left), 10MV-LPO field (top right), 
showing lung (blue), cord (cyan), esophagus (orange), γ-Target (red), JCT (green), and e-
Target (yellow). IM-BECT field intensity map (bottom right). BECT/IM-BECT electron 
field (bottom left) showing γ-Target (red), JCT (green), and e-Target (blue). 
56 
 
Figure 2.16 displays IDL for the CW2 BECT+IMXT plan in transverse planes through 
the superior γ-Target portion of PTV and its JCT portion. The dose distribution in the γ-Target 
CT slice is hour-glass shaped, typical of a parallel opposed beam arrangement. This distribution 
results in shallow anterior and posterior areas of 105% prescribed dose as seen by the 5250 cGy 
IDL in regions outside the PTV. The PTV is not fully covered by 50 Gy in the superior γ-Target 
or JCT slices but is fully covered by 47.5 Gy (95% prescribed dose). The esophagus, located 
patient-left and posterior to the trachea lied in the medial IMXT penumbra and received doses up 
to 50 Gy. 
Figure 2.17 displays IDL for the CW2 BECT+IMXT plan in a transverse plane through 
the inferior e-Target portion of PTV and in one sagittal plane through the heart. The distribution 
in the transverse e-Target CT slice shows two hotspots in the medial and lateral regions of the 
PTV. In the sagittal CT slice, the JCT region of the PTV is shown to have a discontinuity in the 
50 Gy coverage, the e-Target region has a 110% (55.55 Gy) hotspot. 
Figure 2.18 displays IDL for the IM-BECT+IMXT plan in transverse planes. The 
distribution in the γ-Target CT slice is again typical of parallel opposed beams. In the JCT region 
CT slice the overlapping IM-BECT and IMXT dose distributions cover more of PTV with 50 Gy 
compared to the BECT-IMXT plan.  However, 105% hotspots are found in the medial and lateral 
sides of the JCT region.  
Figure 2.19 displays IDL for the IM-BECT+IMXT plan in transverse and sagittal planes. 
The distributions in the transverse e-Target slices show a removal of the hotspots previously seen 
in the BECT+IMXT plan. However, along with the hotspot removal, surface dose is decreased 
with the use of IM-BECT, i.e. without IM the effect of >100% maximum dose and low surface  
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Figure 2.16 CW2-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0,40.0, 30.0, 15.0, 
and 5.0 [Gy] IDL. 
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Figure 2.17 CW2-13 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) and 
sagittal CT slice (bottom) showing PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0,40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure 2.18 CW2-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0,40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure 2.19 CW2-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice (bottom) showing PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0,40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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dose of a 13 MeV beam offset each other. In the sagittal CT slice through the heart, PTV is 
covered well by the 47.5 Gy IDL except for the reduced surface dose proximal to the location 
where the 110% hotspot, seen in the BECT+IMXT plan, has been removed. In the sagittal plane 
through the heart, there is continuity of 50 Gy across the central JCT region compared to the 
slight discontinuity found in the BECT+IMXT plan. However, the 52.5 Gy IDL shows a small 
105% hotspot on the inferior side of the field abutment. 
The CW2 DVHs in Figure 2.20 and Figure 2.21 for PTV, γ-Target, and critical structures 
(lung, heart, cord, contralateral breast, and esophagus) for are similar for the IM-BECT+IMXT 
and BECT+IMXT plans. Both deliver a dose of 50 Gy or more to 50% of PTV. There are no 
noticeable differences in the DVHs for the OARs. The OAR DVH show that low relative 
volumes (<5%) of spinal cord, contralateral breast, and contralateral lung receive doses above 5 
Gy. The total lung volume receiving 20 Gy or more is well below the 20% volume threshold for 
increased risk of pneumonitis. There also appears to be little to no volume of heart receiving 30 
Gy or more, which is the threshold for increased risk of cardiac mortality.  
The BECT+IMXT plan had a PTV V95%(47.5Gy) of 94.9%. The Dmin, Dmax, and Dmean doses 
to PTV were 46.1, 53.5, and 50.1 Gy, respectively, with a standard deviation of 1.7 Gy. The 
heart V30Gy was 0.2% and Dmin, Dmax, and Dmean doses to heart were 0.7, 23.5, and 3.7 Gy, 
respectively, with a standard deviation of 5.7 Gy. The lung V20Gy was 14% and Dmin, Dmax, and 
Dmean doses to lung were 0, 43.7, and 6.4 Gy, respectively, with a standard deviation of 11.8 Gy. 
The IM-BECT+IMXT plan had a PTV V95%(47.5Gy) of 95.1% and the Dmin, Dmax, and Dmean doses 
to PTV were 45.6, 53.7, and 50.3 [Gy], respectively, with a standard deviation of 1.7 Gy. The 
heart V30Gy was 0.2% and Dmin, Dmax, and Dmean doses to heart were 0.8, 23.2, and 3.7 Gy,  
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Figure 2.20 CW2-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines): 
(Top) DVH are shown for PTV (red), esophagus (orange), total lung (blue), heart (pink), 
contralateral breast (forest green), contralateral lung (yellow), and spinal cord (cyan). 
(Bottom) DVH is for the e-Target (blue) showing less volume of high dose for IM-
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Figure 2.21 CW2-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines): 
DVH for the γ-Target (red) and JCT (green). The plan normalization method resulted in a 
slightly cooler JCT dose for the BECT+IMXT(2fld) plan. 
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respectively, with a standard deviation of 5.6 Gy. The lung V20Gy was 13.8% and Dmin, Dmax, and 
Dmean doses to lung were 0, 43.4, and 6.3 Gy, respectively, with a standard deviation of 11.7 Gy. 
ii. Review of 13 MeV CW3 plans using the IMXT(2fld) component 
 
For CW3, the upper left and right BEV in Figure 2.22 depict the 6MV-RAO and 10MV-
LPO IMXT fields, respectively. The lower right and left BEV depict the intensity modulation 
map for the 13 MeV IM-BECT field and the electron aperture for both the BECT and IM-BECT 
fields, respectively.  In the x-ray BEV there is γ-Target, JCT, and lung overlap while the heart, 
cord, and esophagus are completely outside of the x-ray fields. The electron intensity modulation 
map again shows that within the field there were generally more red areas of increased intensity 
with localized blue zones of decreased intensity near the medial and lateral sides. The minimum 
and maximum intensity modulation factors were 0.8 and 1.1, respectively. 
The CW3 DVHs in Figure 2.23 and Figure 2.24 show that both IM-BECT+IMXT plan 
and the BECT+IMXT plan deliver a dose of 50 Gy or more to 60% of the PTV. The DVH for the  
e-Target shows slightly less volume of high dose with IM-BECT+IMXT. For most OAR, except 
heart and lung, only low volumes received doses above 5 Gy. The total lung V20Gy≤20% and 
there is little heart receiving 30 Gy or more. Reductions in treated volumes of lung and heart 
were observed for the IM-BECT+IMXT plan compared to the BECT+IMXT plan. 
The BECT+IMXT plan had a PTV V95%(47.5Gy) of 95.0% and Dmin, Dmax, and Dmean doses 
to PTV were 46.1, 54.9, and 50.8 Gy, respectively, with a standard deviation of 1.9 Gy. The 
heart V30Gy was 1.2% and Dmin, Dmax, and Dmean doses to heart were 0.7, 28.0, and 4.9 Gy, 
respectively, with a standard deviation of 7.2 Gy. The lung V20Gy was 19.6% and Dmin, Dmax, and 
Dmean doses to lung were 0, 46.8, and 9.2 Gy, respectively, with a standard deviation of 14.4 Gy.  
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The IM-BECT+IMXT plan had a PTV V95%(47.5Gy) of 95.0% and the Dmin, Dmax, and Dmean 
doses to PTV were 46.1, 53.9, and 50.6 [Gy], respectively with a standard deviation of 2.2 Gy. 
The heart V30Gy was 0.3% and the Dmin, Dmax, and Dmean doses to heart were 0.8, 24.8, and 4.2 
Gy, respectively with a standard deviation of 6.2 Gy. The lung V20Gy was 18.6% and the Dmin,  
Figure 2.22 CW3-13 MeV BEV: 6MV-RAO field (top left), 10MV-LPO field (top right), 
showing lung (blue), cord (cyan), esophagus (orange), γ-Target (red), JCT (green), and e-
Target (yellow). IM-BECT field intensity map (bottom right). BECT/IM-BECT electron 
field (bottom left) showing γ-Target (red), JCT (green), and e-Target (blue).   
66 
 
  
Figure 2.23 CW3-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines): 
(Top) DVH are shown for PTV (red), esophagus (orange), total lung (blue), heart (pink), 
contralateral breast (forest green), contralateral lung (yellow), and spinal cord (cyan). 
(Bottom) DVH is for the e-Target (blue) showing a warmer IM-BECT+IMXT plan overall, 
but without the hot spot in the BECT+IMXT plan. 
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Figure 2.24 CW3-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH for the γ-Target (red) and JCT (green). 
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Dmax, and Dmean doses to lung were 0.0, 43.8, and 8.3 Gy, respectively with a standard 
deviation of 13.3 Gy. 
iii. Review of 13 MeV CW6 plans using the IMXT(2fld) component 
 
For CW6, the upper left and right BEV in Figure 2.25 depict the 6MV-RAO and 10MV-
LPO IMXT fields, respectively. The lower right and left BEV depict the intensity modulation 
map for the 13 MeV IM-BECT field and the electron aperture for both the BECT and IM-BECT 
fields, respectively.  In the x-ray BEV there is γ-Target, JCT, and lung overlap while the heart, 
cord, and esophagus are fully outside of the x-ray fields. The electron intensity modulation map 
shows that within the field there were more areas of increased intensity than decreased intensity. 
The minimum and maximum intensity modulation factors 0.853 and 1.1, respectively. 
The CW6 DVHs in Figure 2.26 and Figure 2.27 show that both the IM-BECT+IMXT 
plan and the BECT+IMX deliver a dose of 50 Gy or more to 60% of the PTV. Low relative 
volumes (<5%) of most OAR, including esophagus, receive doses above 5 Gy. The total lung 
V20Gy≤20% and there are low heart volumes receiving 30 Gy or more. Like CW3, small 
reductions in treated volumes of lung and heart were noted for the IM-BECT+IMXT plan 
compared to the BECT+IMXT plan. The BECT+IMXT plan had a PTV V95%(47.5Gy) of 94.7% 
and the Dmin, Dmax, and Dmean doses to PTV were 46.0, 53.9, and 50.5 Gy, respectively, with a 
standard deviation of 1.8 Gy. The heart V30Gy was 3.4% and the Dmin, Dmax, and Dmean doses to 
heart were 0.77, 33.27, and 5.97 [Gy], respectively, with a standard deviation of 8.6 Gy. The 
lung V20Gy was 18.1% and the Dmin, Dmax, and Dmean doses to lung were 0, 48.58, and 8.92 [Gy], 
respectively, with a standard deviation of 15.12 Gy. 
The IM-BECT+IMXT plan had a PTV V95%(47.5Gy) of 94.8% and Dmin, Dmax, and Dmean 
doses to PTV for were 45.4, 53.1, and 50.3 Gy, respectively, with a standard deviation of 1.7 Gy.  
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The heart V30Gy was 2.2% and Dmin, Dmax, and Dmean doses to heart were 0.8, 30.5, and 5.4 
Gy, respectively, with a standard deviation of 7.8 Gy. The lung V20Gy was 17.8% and the Dmin, 
Dmax, and Dmean doses to lung were 0, 47.8, and 8.7 Gy, respectively, with a standard deviation of 
14.9 Gy. 
Figure 2.25 CW6-13 MeV BEV: 6MV-RAO field (top left), 10MV-LPO field (top right), 
showing lung (blue), cord (cyan), esophagus (orange), γ-Target (red), JCT (green), and e-
Target (yellow). IM-BECT field intensity map (bottom right). BECT/IM-BECT electron 
field (bottom left) showing γ-Target (red), JCT (green), and e-Target (blue).   
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Figure 2.26 CW6-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines): 
(Top) DVH are shown for PTV (red), esophagus (orange), total lung (blue), heart (pink), 
contralateral breast (forest green), contralateral lung (yellow), and spinal cord (cyan). 
(Bottom) DVH is for the e-Target (blue) showing less volume of high dose for the IM-
BECT+IMXT. 
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Figure 2.27 CW6-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH for the γ-Target (red) and JCT (green). 
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2.2.2.2 Review of13 MeV BECT+IMXT(3fld) and IM-BECT+IMXT(3fld) 
The addition of the third 6MV-AP field allowed for the MLC leaf travel to be 
perpendicular to the length of the esophagus, as seen in the upper right BEV in Figure 2.28. CW2 
was only patient for which an IMXT(3fld) component was used in a trial plan. This plan led to 
an improvement in a high esophagus dose, which was found with the IMXT(2fld) trial plan. The 
representative tangent BEV and electron intensity map are identical to those in the 
BECT+IMXT(2fld) and IM-BECT+IMXT(2fld) plans. In the 6MV-AP BEV, there is a larger 
amount of γ-Target, JCT, and lung overlap compared to the representative tangent BEV, as well 
as some esophagus overlap. Due to the esophagus overlap in the tangent BEV, as well as AP 
BEV, the main benefit of the third field to the esophagus is believed to be due to the additional 
collimator orientation which allowed for allowed for MLC leaf travel perpendicular to the length 
of the esophagus rather than the field junction.  
Figure 2.29 displays IDL for the BECT+IMXT(3fld) plan in transverse planes through 
the superior γ-Target portion of PTV and its JCT portion. The three-field IMXT distribution in  
the γ-Target CT slice results in full PTV coverage with 95% prescribed dose with reduced high 
dose (>40 Gy) volume and increased low dose (5-40 Gy) volume of treated posterior NT 
compared to the BECT+IMXT(2fld) trial plan. In the JCT CT slice, the overlapped BECT and 
parallel opposed IMXT dose distributions also fully cover the PTV with 95% dose.  
Figure 2.30 displays IDL for the BECT+IMXT(3fld) plan in a transverse plane through 
the inferior e-Target portion of PTV and in one sagittal plane through the heart. The distribution 
in the transverse e-Target CT slice shows hotspots in the medial and lateral regions of the PTV. 
There is also a lateral portion of the PTV that has decreased surface dose and a lack of coverage  
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by the 47.5 Gy IDL. In the sagittal CT slice, there is reduced 50 Gy coverage superiorly and 
increased lung volume receiving 5 Gy compared to the BECT+ IMXT(2fld) trial plan. 
  
Figure 2.28 CW2-13 MeV(3fld) BEV: 6MV-RAO representative tangent field (top left), 
6MV-AP field (top right), showing lung (blue), cord (cyan), esophagus (orange), γ-Target 
(red), JCT (green), and e-Target (yellow). IM-BECT field intensity map (bottom right). 
BECT/IM-BECT electron field (bottom left) showing γ-Target (red), JCT (green), and e-
Target (blue).   
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Figure 2.29 CW2-13 MeV BECT+IMXT(3fld):  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 4500,4000, 
3000, 1500, and 500 [cGy] IDL. 
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Figure 2.30 CW2-13 MeV BECT+IMXT(3fld): Transverse CT slice through the e-Target 
(top) and sagittal CT slice (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 
4500,4000, 3000, 1500, and 500 [cGy] IDL. 
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 Figure 2.31 displays IDL for the IM-BECT+IMXT(3fld) plan in transverse planes 
through γ-Target and JCT CT slices. The distribution in the γ-Target CT slice (top) again shows 
the PTV is covered well with 95% prescribed dose. There is again a reduced high dose volume of 
treated posterior NT and a wider low dose (<5 Gy) bath compared to plans to the IM-
BECT+IMXT(2fld) plan. In the JCT region CT slice (bottom) the overlapped IM-BECT and 
IMXT(3fld) dose distributions result in slightly more patches of PTV coverage with 50 Gy 
compared to the BECT+IMXT(2fld) plan.  
Figure 2.32 displays IDL for the IM-BECT+IMXT(3fld) plan in transverse and sagittal 
planes. The distribution in the transverse e-Target CT slice shows a reduction of hotspots and 
increased coverage of the cold lateral area of the PTV compared to the BECT+IMXT plan. 
Again, decreased surface dose is seen because of the removal of hotspots. In the sagittal CT slice 
(bottom), PTV is covered well by the 47.5 Gy IDL, but there is increased lung volume receiving 
5 Gy and a large loss of 50 Gy coverage superiorly compared to the IM-BECT+IMXT(2fld) 
plan. 
The CW2 DVHs in Figure 2.33 for PTV and critical structures (lung, heart, cord, 
contralateral breast, and esophagus) are nearly identical for the BECT+IMXT(3fld) and IM-
BECT+IMXT(3fld) plans. Both deliver a dose of approximately 50 Gy or more to 50% of PTV. 
There are no noticeable differences in the DVHs for the OARs.  Esophagus doses above 20 Gy 
are limited to low relative volume (<5%). Though there was an increase in the low dose bath for 
the lung using the IMXT(3fld) trial plan, the lung V20Gy is still well below 20%. The 
BECT+IMXT(3fld) plan had a PTV V95%(47.5Gy) of 96.4% and the Dmin, Dmax, and Dmean doses to 
PTV were 46.6, 53.2, and 50.7 Gy, respectively, with a standard deviation of 1.5 Gy. The heart 
V30Gy was 0.2% and the Dmin, Dmax, and Dmean doses to heart were 0.7, 23.4, and 3.7 Gy, 
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Figure 2.31 CW2-13 MeV IM-BECT+IMXT(3fld):  Transverse CT slices through the γ-
Target (top) and JCT (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 
4500,4000, 3000, 1500, and 500 [cGy] IDL. 
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Figure 2.32 CW2-13 MeV IM-BECT+IMXT(3fld): Transverse CT slice through the e-Target 
(top) and sagittal CT slice (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 
4500,4000, 3000, 1500, and 500 [cGy] IDL. 
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respectively, with a standard deviation of 5.7 Gy. The lung V20Gy was 13.4% and the Dmin, Dmax, 
and Dmean doses to lung were 0, 44.3, and 6.7 Gy, respectively, with a standard deviation of 11.8 
Gy.  
The IM-BECT+IMXT(3fld) plan had a PTV V95%(47.5Gy) of 95% and Dmin, Dmax, and 
Dmean doses to PTV were 45.5, 52.5, and 50.3 Gy, respectively, with a standard deviation of 1.6 
Gy. The heart V30Gy was 0.1% and Dmin, Dmax, and Dmean doses to heart were 0.7, 23.1, and 3.7 
Gy, respectively, with a standard deviation of 5.6 Gy. The lung V20Gy was 17.8% and the Dmin, 
Dmax, and Dmean doses to lung were 0.0, 43.8, and 6.7 [Gy], respectively, with a standard 
deviation of 11.7 Gy. 
Figure 2.33 CW2-13 MeV BECT+IMXT(3fld) (solid lines) and IM-BECT+IMXT(3fld) 
(dashed lines): DVH are shown for PTV (red), esophagus (orange), total lung (blue), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), and spinal cord (cyan). 
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2.2.2.3 13 MeV CW2 BECT+IMXT(3fld) and IM-BECT+IMXT(2fld) Comparison 
The CW2 DVHs in Figure 2.34 for PTV, lung, and esophagus reveal some difference 
between the BECT+IMXT(3fld) and BECT+IMXT(2fld) plans. The lung volume for the 
BECT+IMXT(3fld) plan increases for doses below 10 Gy compared to the BECT+IMXT(2fld). 
However, esophagus sparing is increased with the use of the AP x-ray field. The volume of 
esophagus receiving high doses of 30 and 40 Gy or more in the BECT+IMXT(2fld) plan have 
been reduced approximately 7% and 4%, respectively with the BECT+IMXT(3fld) plan. There 
also appears to be an improvement in the overall dose uniformity within PTV for the three-field 
arrangement. The PTV DVH for the BECT+IMXT(3fld) plan falls off more sharply from 47.5 
Gy than the BECT+IMXT(2fld) plan. 
Figure 2.34 CW2-13 MeV BECT+IMXT(3fld) (solid lines) and BECT+IMXT(2fld) (dashed 
lines): DVH are shown for PTV (red), esophagus (orange), total lung (blue), heart (pink), 
contralateral breast (forest green), contralateral lung (yellow), and spinal cord (cyan). 
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2.3 Discussion & Conclusion 
Using a test set of three patients, a potentially clinically acceptable treatment planning 
strategy was developed for IM-BECT and BECT for the inferior-left CW abutted to parallel 
opposed IMXT beams for any remaining superior PTV.  
The strategy is composed of six primary elements:  
1) Selection of electron energy, and beam geometry at 105 cm SSD (e.g. gantry angle 
and field size), such that electron coverage of the PTV with 47.5 Gy (95% prescribed 
dose) is possible superior to the superior extent of the heart.     
2) Selection of parallel opposed 6MV-RAO and 10MV-LPO x-ray beam geometries 
such that their inferior and medial beam sides are HBB, and the inferior beam sides 
are parallel to the superior electron beam side with a 1.5 cm overlap. 
3) Segmentation of the PTV into an inferior e-Target (i.e. the target to be treated with  
BECT or IM-BECT), a JCT region (i.e. a 3 cm field junction region of the PTV 
superior to the e-Target to be treated by optimizing the IMXT fields on top of the 
BECT or IM-BECT dose distributions), and a superior γ-Target (i.e. the remainder of 
the PTV to be treated with IMXT). 
4) Design of patient-specific bolus for BECT or IM-BECT by applying bolus design 
operator sequences (Section 2.1.6) shown to yield acceptable dose distributions for 13 
and 16 MeV electron beams.  
5) Optimization of tangent parallel opposed IMXT beams to improve dose uniformity in 
the JCT and coverage of the γ-Target in a region of varying patient thickness. 
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6) Plan normalization, i.e. adjustment of electron and photon beam weight, during and 
after IMXT optimization, respectively, to achieve 95% PTV coverage with 95% of 
the prescribed dose. 
An electron energy study, which compared BECT+IMXT and IM-BECT+IMXT plans at 
13, 16, and 20 MeV, determined no lung benefit with increased electron energy, and the 
according gain in superior BECT or IM-BECT PTV coverage. Thus, the treatment planning 
strategy uses the minimum electron energy required to achieve BECT or IM-BECT coverage of 
the PTV to no less than the superior extent of the heart. The energy study also determined that 
for the three test patients: PTV-V95 ≥ 95%, Lung-V20Gy < 20%, and Heart-Dmean < 8 Gy were 
achieved at 13 MeV; only PTV-V95 ≥ 95% and Heart-Dmean < 8 Gy were achieved at 16 MeV; 
and only PTV-V95 ≥ 95% was achieved at 20 MeV. For one patient (CW2), Lung-V20Gy < 20% 
was achieved at 16 MeV. 
Since the test patients had been previously treated using VMAT, the physician contoured 
PTVs did not distinguish the IMN, AX, or CW from the SC. A common practice using mixed-
beam techniques to treat the CW with electrons or x-ray tangents and the superior PTV with 
more anterior or posterior x-rays, which are known to provide better medial coverage of the SC 
at depth (Pierce 2002). In the treatment planning strategy developed here, the use of IMXT 
tangents to treat the remaining superior CW and SC portion of the PTV (i.e. γ-Target) provided 
full coverage of the γ-Target with at least 95% prescribed dose.  
One issue with this arrangement, i.e. the IMXT(2fld) tangents, however, was that due to 
body habitus the patient separation for tangents was larger than it would be for more anterior-
posterior x-rays. Since the PTV lied to the anterior side of this wider patient separation using 
tangents, there was an excess dosage of posterior NT in CT slices near the clavicle. Another 
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issue with the IMXT(2fld) tangents was that due to the proximity of the PTV and esophagus for 
CW2, the maximum esophagus dose (approximately 50 Gy) was very high compared to CW3 
and CW6 (which were within approximately 2-5 Gy). A comparison of the IMXT(2fld) and the 
IMXT(3fld) arrangement for CW2 showed that the maximum esophagus dose was reduced to 
approximately 40 Gy, and the relative esophagus volume receiving 20-30 Gy was reduced by 
approximately 8% with the addition of the 6MV-AP IMXT field. As seen in the isodose plots for 
CW2, the IMXT(3fld) arrangement also reduced the excess posterior NT treated with 50 Gy or 
more compared to the IMXT(2fld) arrangement. However, the IMXT(3fld) arrangement also led 
to an increase of the low dose bath (i.e. the volume of NT receiving 5 Gy) and the relative lung 
volume receiving 5 Gy (approximately 6%) compared to the IMXT(2fld) technique.  
In conclusion, the treatment planning strategy presented here has been shown to provide 
potentially clinically acceptable treatment plans using 13 MeV and 16 MeV BECT or IM-BECT 
(for 3/3 and 1/3 test patients, respectively) to treat the inferior-left CW abutted to parallel 
opposed IMXT beams for any remaining superior PTV. This conclusion is based on the three 
PMRT PTV and OAR criteria we used to define potential clinical acceptability (i.e. PTV-V95 ≥ 
95%, Lung-V20Gy < 20%, and Heart-Dmean < 8 Gy BECT). However, the combined use of BECT 
of IM-BECT to treat the inferior-left CW and IMXT tangents to treat the remaining superior 
PTV is not common practice and the overall technique still requires further study.    
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Chapter 3. Aim 2 – Generate Plans and Metrics 
 
 Aim 2 was to generate BECT+IMXT and IM-BECT+IMXT treatment plans for the 
remaining six patients using the strategy developed in Aim 1. Also, for all patients, to calculate 
dose metrics for the lower-left CW electron PTV subtarget, the PTV, and specific OARs, as well 
as biological metrics for tumor control probability (TCP), normal tissue complication probability 
(NTCP), and second cancer complication probability (SCCP). 
3.1 Treatment Planning Methods 
 
In aim 2 each patient was planned with the two-field parallel opposed IMXT arrangement 
described in Aim 1. The electron beam energy and field size were determined using the methods 
described in Aim 1. Next, the BECT and IM-BECT plan components were designed using the 
same bolus design operator sequences described in Aim 1. Finally, the same plan normalization 
criteria (i.e. such that V95%(47.5Gy) = 95%) was used.  
 
3.2 Metric Calculation Methods 
 
Cumulative DVHs for the PTV, e-Target, and each OAR were exported from Pinnacle 
with a dose bin width of 1 cGy. In Matlab, the differential dose volume histogram (dDVH) of the 
PTV and specific OARs were calculated from the cumulative DVHs and the following metrics 
were then computed from either the DVH or dDVH.  
3.2.1 Treated Volume (TV), PTV, and e-Target metrics 
 The following metrics were calculated for the PTV: 
 
1. Dmin, Dmax, Dmean, and standard deviation (SD) 
2. TV-V110%: Percent volume of the treated volume (TV) given 55 Gy (110% of the 
prescribed dose),  where TV = Volume of patient given prescribed dose of 50 Gy. 
3. Dmin, Dmax, & Dmean  
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DHI = D>?@ − D>ABDC@ 		, (3.2) 
4. Dose received by 95% of the PTV, PTV-D95% 
5. D95%: Dose given to 95% PTV volume 
6. V95%: Percent PTV volume given 47.5 Gy (95% of the prescribed dose)  
7. CI: Conformity Index 
 
 The following metrics were calculated for the PTV and e-Target separately: 
 
1. V107%: Percent volume given 53.5 Gy (107% of the prescribed dose) 
2. V110%: Percent volume given 55.0 Gy (110% of the prescribed dose) 
3. Dose homogeneity index (DHI) 
4. Tumor control probability 
5. The FWHM of the differential DVH  
 
As large volumes of dose greater than the prescribed dose can lead to acute skin toxicity 
(Chen 2010), the PTV-V107% and PTV-V110% were computed to evaluate the PTV dose 
homogeneity along with the DHI. For a similar evaluation of every volume of the patient 
receiving the prescribed dose (i.e. not only volumes within the PTV), the TV-V110% described by 
Chen et al. (2010) was calculated using the volume of the patient that received 110% of the 50 
Gy prescribed dose (V55Gy) and the TV defined as the volume of the patient that received the 
prescribed dose (V50Gy). TV-V110% was calculated as 
For a 50.4 Gy prescription dose, Chen et al. have shown that a PTV-V107% > 28.6% or a TV-
V110% > 5.1% and no prophylactic topical therapy for irradiated skin were associated with higher 
incidence of acute radiation dermatitis. 
The DHI was defined as 
where Dmin and Dmax were defined as the doses given to at least 98% volume and 2% volume, 
respectively, of the PTV or e-Target, and DRx was the prescription dose (Wu 2003). Ideally, the 
DHI is nearly zero, meaning the dose within the PTV is homogeneous. 
 TV−VFFG% = VHHIJVHGIJ 	 ∙ 100	, (3.1) 
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 TCP =OTCPA		,
A
 (3.4) 
 TCPA = eQRS∙TUS 		. (3.5) 
 NA = ρXVA		, (3.6) 
 SFA = e(Q[\SQI]\S^ )	, (3.7) 
The CI was defined as 
where TVRI was the volume of the PTV that received the reference dose of 47.5 Gy (95% 
prescribed dose) (van't Riet 1997), TVtot was the total volume of the PTV ROI, and VRI was the 
volume of the patient that received the reference dose (volumes of irradiated bolus were not 
included in VRI).  Ideally, CI is near unity, which means the reference dose is highly conformal 
to the distal border of the PTV ROI. 
The TCP for the PTV was calculated using the model described by Webb and Brenner et 
al.(Webb 1993). In this model, TCP is determined by the product of tumor control in each sub-
volume Vi of the PTV dDVH as  
where TCPi is the probability of controlling the tumor cells in each sub-volume i, as 
In equation 3.5, Ni, the number of tumor cells in each sub-volume i, was determined by  
where ρc is the density of tumor cells and Vi is the volume irradiated to a dose of Di. SFi, the 
surviving fraction of cells in a sub-volume i, is predicted with the linear-quadratic model for cell 
survival given by  
where Di is the dose per fraction in Gy to sub-volume i, α, the rate of lethal cell damage, and β, 
the rate of sublethal cell damage. G accounts for fractionation and the half-time for sublethal 
 CI = TVC_TV` a` ×
TVC_VC_ 		, (3.3) 
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 NTCP = 	 1√2πf e
Q@^g`
Qh dx, (3.9) 
 G = 1x		, (3.8) 
Table 3.1 Parameters used in calculating TCP 
Parameter Value 
ρc 1.0x107 cm-3[a] 
α 0.51 Gy-1 [b,c,d] 
β 0.061 Gy-2[b,c,d] 
G 0.04[d]
 
Parameters sourced from: a) Webb et al (1993), b) Nichols (2012), c) Hernandez (2014), 
and d) Heins (2016) 
cell damage as 
where x is the number of fractions. In the absence of α and β values for chest wall, those for 
whole breast have been used as in other PMRT studies (Hernandez 2014, Nichols 2014, Heins 
2016). Table 3.1 lists the parameters used in the calculation of TCP. 
3.2.2 OAR metrics  
The following metrics were calculated for specific OARs: 
 
1. Dmin, Dmax, Dmean, & SD 
2. Lung V5Gy, V10Gy, & V20Gy  
3. Heart V5Gy, V10Gy, & V22.5Gy, & V30Gy 
4. Contralateral Breast V5Gy 
5. NTCP: Normal Tissue Complication Probability 
6. SCCP: Second Cancer Complication Probability  
 
3.2.2.1 NTCP  
NTCP for total lung volume was calculated with radiation pneumonitis grade two or 
higher as an endpoint. The Lyman-Kutcher-Burman (LKB) (Lyman 1985, Seppenwoolde 2003) 
model was used to calculate NTCP for the lungs where 
where  
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 EUD = noDAFB
A
VAV` a`p
B
. (3.11) 
 NTCP = q1 −O(1 − P(DA)r)sS
A
t
F r2
 
(3.12) 
where  
Since an inhomogeneous dose distribution was calculated in the lung, the lung dDVH was 
reduced to an equivalent uniform dose (EUD) according to Seppenwoolde et al. using equation 
3.11 where n is the volume effect parameter, Di is the dose per fraction in Gy to sub-volume i, Vi 
is the volume irradiated to dose Di and Vtot is the total lung volume.  In equation 3.10, m is a 
measure of the slope of the dose-response curve; EUD is the dose that, if given uniformly to the 
total lung volume, results in the same NTCP as a non-uniform dose distribution; and TD50 is the 
equivalent uniform dose given to the organ that results in a 50% risk of complication. Table 3.2 
provides all parameters used to calculate lung NTCP.  
NTCP for whole heart and myocardium as calculated using the relative seriality model 
(Kallman 1992) which accounts for the series and parallel spatial arrangement of functional 
subunits within organ tissues. NTCP was calculated using the dDVH for whole heart and 
myocardium with cardiac mortality as an end point by  
Table 3.2 Parameters used in calculating lung NTCP 
Parameter Value   
m 0.37  
 n 0.99  
TD50 30.8 Gy  
Parameters sourced from Seppenwoolde (2003) 
 t = 	EUD −	TDHGm ∙ TDHG , (3.10) 
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where Di is the dose in Gy sub-volume i, Vi is volume irradiated to dose Di, and s is the organ’s 
relative seriality (i.e. the ratio of serially arranged subunits to total functional subunits). 
Probability of complication as a function of dose, P(Di), is defined as 
where γ is the maximum relative slope of the dose-response curve and TD50 is a total dose that if 
given uniformly to the organ results in a 50% risk of complication. Table 3.3 provides 
parameters used to calculate whole heart and myocardium NTCP.
 
Minimization of secondary 
cancer risk, especially for contralateral is a concern when considering different PMRT 
techniques. 
3.2.2.2 SCCP  
SCCP has been calculated for the contralateral breast and lung as in other PMRT 
planning studies involving electron beams (Ashenafi 2010, Heins 2016). Using the Schneider 
model (Schneider 2005), SCCP has been calculated for both a linear dose response (SCCPl) and 
a linear-exponential dose response (SCCPle) as  
 P(DA) = 2Qwxyz{/
|S|}~
 
(3.13) 
Table 3.3 Parameters used in calculating whole heart and myocardium NTCP 
Structure Parameter Value 
Whole Heart 
TD50 52.3 Gy 
γ 1.28 
s 1 
Myocardium 
TD50 52.2 Gy 
γ 1.25 
s 0.87 
Parameters sourced from Gagliardi (2001), Hernandez (2014) 
 SCCP = InaOEDa,ABw?	, (2.14) 
 SCCPw = InaOEDa,ABw?Qw@aBwB`A?	, (2.15) 
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where Inorg is the organ specific absolute cancer incidence as a percentage per gray representing 
the lifetime risk for a residual lifetime expectancy of 50 years. OEDorg is the organ equivalent 
dose in gray representing an inhomogeneous dose distribution, which if given uniformly would 
result in the same cancer incidence (Schneider 2005). Using both linear and linear-exponential 
dose-response models (Abo-Madyan 2014), OEDorg was calculated from dDVH for lung and 
contralateral breast by 
where, α is an organ specific cell sterilization parameter, Di is the dose in Gy to sub-volume i, Vi 
is the volume irradiated to dose Di, and the summation is over the total organ volume Vorg. Table 
3.4 provides parameters used to calculate contralateral breast and lung SCCP.  
 
3.3 Treatment Planning Results 
 
For the patients generated in Aim 1, 13 MeV electrons were sufficient for CW coverage 
superiorly through the superior extent of the heart for all three patients. For the remaining six 
patient plans in Aim 2, the BECT and IM-BECT components required using 16 MeV electrons 
for all patients except for CW8, for which 13 MeV sufficed. All nine patient plans met the 
 OEDa,ABw? = 1VaoVADAA 		, (2.16) 
 OEDa,ABw?Qw@aBwB`A? = 1VaoVADAA e
Q[\S 	, (2.17) 
Table 3.4 Parameters used in calculating contralateral breast and lung SCCP 
Organ Parameter Value 
Breast α 0.085 Gy
-1
 
Inorg 0.78 %‧Gy-1 
Lung α 0.085 Gy
-1
 
Inorg 1.68 %‧Gy-1 
Parameters sourced from Schneider (2005)  
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requirements for potential clinical acceptability given in Section 2.1.10, except for CW7 IM-
BECT+IMXT which failed to meet the requirement of Heart-Dmean < 8 Gy. This plan resulted in 
a Heart-Dmean of 8.28 Gy for IM-BECT+IMXT compared to 7.61 Gy with the BECT+IMXT 
plan.  Appendix A. provides DVHs and plots of IDL in transverse and sagittal planes through the 
γ-Target, JCT, and e-Target for each set of final BECT+IMXT and IM-BECT plans generated 
for the nine patients. 
3.4 Plan Metrics Results 
 
3.4.1 PTV metrics 
The average PTV: Dmin, Dmax, and Dmean doses for BECT+IMXT plans were 46.1, 54.4, 
and 50.5 Gy, respectively compared to 45.7, 53.7, and 50.4 Gy, respectively, for the IM-
BECT+IMXT plans. The changes in the average PTV: Dmin, Dmax, and Dmean doses in IM-
BECT+IMXT plans relative to BECT+IMXT plans were -0.4, -0.7, and -0.1 Gy, respectively. 
Table 3.5 shows the PTV Dmean, SD, D95%, V95%, and CI for each plan. In the plan column of 
Table 3.5 the entries “CW1” and “CW1-IM”, for example, stand for the BECT+IMXT and IM-
BECT+IMXT plans for patient CW1.  
The average PTV: D95% and V95%, for IM-BECT+IMXT and BECT+IMXT plans were 
identical (47.5 Gy and 95.0%, respectively), which shows that plan normalization was conducted 
without bias.  The small change in the PTV CI (0.001), where larger CI represents higher dose 
conformity, shows that on average, IM-BECT+IMXT plans had no negative impact on dose 
conformity. The average TV-V110% with BECT+IMXT was 3.3%, whereas with IM-
BECT+IMXT it was reduced to 2.6% indicating more homogeneous dose in the TV on average. 
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Other PTV homogeneity metrics (V107%, V110%, DHI, and the FWHM of the dDVH) are listed for 
each plan in Table 3.6, and revealed additional benefits of IM-BECT, especially when the 
metrics were calculated for the e-Target separately. For the metrics in Table 3.6 that were 
calculated for the e-Target separately, there were only 2 of 36 pairs, the DHI for CW3-IM and  
Table 3.5 PTV Dmin, Dmax, Dmean, SD, D95%, V95%, and CI; and TV-V110% 
 PTV TV 
e- 
Energy Patient 
-Plan 
Dmin Dmax Dmean SD D95% V95% CI V110% 
[MeV] [Gy] [Gy] [Gy] [Gy] [Gy] [%] [%] 
16 CW1 45.7 54.3 50.7 1.9 47.5 95.1 0.362 1.2 
16 CW1-IM 45.8 54.6 51.0 2.0 47.5 94.9 0.368 2.2 
13 CW2 46.1 53.5 50.1 1.7 47.5 94.9 0.336 2.7 
13 CW2-IM 45.6 53.7 50.3 1.7 47.6 95.1 0.334 3.5 
13 CW3 46.1 54.9 50.8 1.9 47.5 95.0 0.324 3.0 
13 CW3-IM 45.1 53.9 50.6 2.2 47.5 95.0 0.334 0.6 
16 CW4 45.7 55.8 51.0 2.6 47.5 94.7 0.335 11.9 
16 CW4-IM 45.6 54.4 50.6 2.1 47.5 95.0 0.344 8.7 
16 CW5 46.3 54.9 50.4 2.0 47.5 95.1 0.350 3.7 
16 CW5-IM 46.0 53.7 50.4 1.8 47.6 95.1 0.350 2.8 
13 CW6 46.0 53.9 50.5 1.8 47.4 94.7 0.333 0.8 
13 CW6-IM 45.4 53.1 50.3 1.7 47.4 94.8 0.336 0.4 
16 CW7 46.4 54.9 50.2 2.0 47.5 95.1 0.352 2.4 
16 CW7-IM 46.3 52.9 49.6 1.6 47.5 95.0 0.349 0.0 
13 CW8 46.0 53.2 50.3 1.6 47.5 95.0 0.346 0.6 
13 CW8-IM 45.4 52.8 50.3 1.6 47.5 95.0 0.346 1.1 
16 CW9 46.2 54.2 50.4 1.9 47.5 95.0 0.36 4.0 
16 CW9-IM 45.8 54.4 50.6 1.9 47.5 95.0 0.346 4.0 
AVG BECT 46.0 54.4 50.5 1.9 47.5 95.0 0.344 3.3 
σ BECT 0.2 0.8 0.3 0.3 0.0 0.2 0.013 3.4 
AVG IM BECT 45.7 53.7 50.4 1.8 47.5 95.0 0.345 2.6 
σ IM-BECT 0.4 0.7 0.4 0.2 0.1 0.1 0.011 2.7 
Change* -0.3 -0.7 -0.1 -0.1 0.0 0.0 0.001 -0.8 
*Note CWX and CWX-IM indicate BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Change equals AVG IM-BECT – AVG BECT, where AVG BECT and AVG IM-BECT are 
metric averages for BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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CW9-IM, that did not show a patient specific benefit of the IM-BECT+IMXT plan for the e-
Target compared to 16 of 36 pairs for the PTV.  
Though a patient specific benefit was not found for all pairs of PTV metrics in Table 3.6 
all the percent changes in the averages, except for the FWHM of the PTV dDVH, showed 
improvement with the use of IM-BECT+IMXT. Because DHI is a function of Dmin and Dmax 
Table 3.6 PTV and e-Target V107%, V110%, DHI, and FWHM of dDVH 
 PTV e-Target 
e- Energy Patient 
-Plan 
V107% V110% DHI FWHM V107% V110% DHI FWHM 
[MeV] [%] [%] [Gy] [%] [%] [Gy] 
16 CW1 5.5 0.5 0.172 3.0 7.9 0.8 0.198 4.2 
16 CW1-IM 6.4 1.2 0.177 3.7 4.4 0.5 0.186 2.8 
13 CW2 2.1 0.1 0.149 3.2 3.0 0.3 0.171 2.8 
13 CW2-IM 2.6 0.0 0.162 2.7 0.0 0.0 0.168 1.6 
13 CW3 7.4 1.7 0.175 3.3 13.1 3.3 0.199 3.0 
13 CW3-IM 5.2 0.1 0.175 4.8 7.8 0.1 0.209 1.6 
16 CW4 17.4 4.8 0.201 6.3 28.6 9.8 0.249 5.5 
16 CW4-IM 6.0 0.7 0.176 3.7 1.1 0.0 0.176 1.4 
16 CW5 6.4 1.8 0.173 2.7 11.8 4.4 0.216 4.4 
16 CW5-IM 2.6 0.1 0.154 3.0 1.0 0.0 0.170 3.4 
13 CW6 3.2 0.5 0.158 0.8 5.7 0.9 0.187 4.0 
13 CW6-IM 0.9 0.0 0.154 2.2 0.1 0.0 0.180 1.8 
16 CW7 6.6 1.8 0.172 1.6 17.4 5.0 0.207 7.0 
16 CW7-IM 0.9 0.0 0.132 1.7 0.5 0.0 0.167 2.8 
13 CW8 1.2 0.1 0.145 1.7 2.5 0.2 0.179 2.5 
13 CW8-IM 0.3 0.0 0.147 1.8 0.0 0.0 0.161 1.3 
16 CW9 4.3 0.7 0.159 2.9 5.3 1.2 0.186 4.6 
16 CW9-IM 4.9 0.8 0.173 3.5 5.0 0.9 0.197 3.2 
AVG BECT 6.0 1.3 0.167 2.8 10.6 2.9 0.200 4.2 
σ BECT 4.8 1.5 0.017 1.6 8.4 3.2 0.023 1.4 
AVG IM BECT 3.3 0.3 0.161 3.0 2.2 0.2 0.180 2.2 
σ IM-BECT 2.4 0.5 0.016 1.0 2.8 0.3 0.016 0.8 
Change* -2.7 -1.0 -0.006 0.2 -8.4 -2.7 -0.020 -2.0 
*Note CWX and CWX-IM indicate BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Change equals AVG IM-BECT – AVG BECT, where AVG BECT and AVG IM-BECT are 
metric averages for BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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doses within the PTV, for which there was little variation between plans, DHI changes less on 
average (-0.006 and -0.020 for the PTV and e-Target, respectively) compared to the changes in 
the average V107%, V110%, and FWHM.  When calculated for the PTV, the average V107% dropped 
2.7% with IM-BECT+IMXT from 6.0% with BECT+IMXT. The average V110%, fell 1.0% with 
IM-BECT+IMXT from 1.3% with BECT+IMXT. However, when calculated for the e-Target 
separately the average V107% and V110% saw greater reductions of 8.4% and 2.7%, respectively, 
from 10.6% and 2.9%, respectively, with BECT+IMXT. This indicates there is a stronger high 
dose volume reduction benefit for the IM-BECT+IMXT plans within the e-Target compared to 
the PTV.  
3.4.2 Lung metrics 
 The average lung doses: Dmin, Dmax, and Dmean for BECT+IMXT plans were 0, 45.7, and 
7.5 Gy, respectively, compared to 0, 44.8, and 7.4 Gy, respectively, for the IM-BECT+IMXT 
plans. The changes in the average lung: Dmin, Dmax, and Dmean doses for IM-BECT+IMXT plans 
relative to BECT+IMXT plans were 0, -0.9, and -0.1 Gy, respectively. Table 3.7 lists the lung: 
Dmean, SD, V5Gy, V10Gy, and V20Gy for each plan. The average lung: V5Gy, V10Gy, and V20Gy for 
BECT+IMXT plans were 26.7, 21.2, and 15.4%, respectively, compared to 26.1, 20.8, and 
15.3%, respectively, with IM-BECT+IMXT. The changes in the average lung: V5Gy, V10Gy, and 
V20Gy for IM-BECT+IMXT relative to BECT+IMXT were -0.6, -0.4, and -0.1%, respectively, 
showing that on average the use of IM-BECT for the CW did not increase the treated lung 
volume. 
3.4.3 Heart metrics 
The average heart: Dmin, Dmax, and Dmean doses for BECT+IMXT plans were 0.9, 26.5, 
and 5.0 Gy, respectively, compared to 0.9, 25.4, and 4.8 Gy, respectively, for the 
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BECT+IMXT plans. The changes in the average heart: Dmin, Dmax, and Dmean doses for IM-
BECT+IMXT plans relative to BECT+IMXT plans were 0, -1.1, and -0.2 Gy, respectively. Table 
3.8 lists the heart: Dmean, SD, V5Gy, V10Gy, V22.5Gy, and V30Gy for each plan. The average heart: 
V5Gy, V10Gy, V22.5Gy, and V30Gy for BECT+IMXT plans were 25.7, 16.3, 4.7, and 1.2%, 
respectively, compared to 24.7, 15.3, 4.1, and 1.0%, respectively, with IM-BECT+IMXT. The  
Table 3.7 Lung Dmin, Dmax, Dmean, SD, V5Gy, V10Gy, and V20Gy 
 Lung 
e- 
Energy 
Patient 
-Plan 
Dmin Dmax Dmean SD V5Gy V10Gy V20Gy 
[MeV] [Gy] [Gy] [Gy] [Gy] [%] [%] [%] 
16 CW1 0.1 46.8 7.8 13.3 27.3 21.1 15.3 
16 CW1-IM 0.1 46.0 7.6 13.0 26.6 21.1 15.7 
13 CW2 0.0 43.7 6.4 11.8 23.6 19.2 14.0 
13 CW2-IM 0.0 43.4 6.3 11.7 22.9 19.0 13.8 
13 CW3 0.0 46.8 9.2 14.4 32.9 26.6 19.6 
13 CW3-IM 0.0 43.8 8.3 13.3 30.2 24.8 18.6 
16 CW4 0.1 39.6 5.2 9.8 20.6 15.4 10.2 
16 CW4-IM 0.1 37.7 5.0 9.5 19.9 15.1 10.0 
16 CW5 0.0 47.2 8.3 13.7 30.1 23.8 16.6 
16 CW5-IM 0.0 46.9 8.2 13.5 29.5 23.4 16.4 
13 CW6 0.1 48.6 8.9 15.1 29.1 23.4 18.1 
13 CW6-IM 0.1 47.8 8.7 14.9 28.2 22.7 17.8 
16 CW7 0.1 46.7 7.4 12.9 25.2 19.8 14.6 
16 CW7-IM 0.1 46.5 7.7 13.1 26.0 20.4 15.0 
13 CW8 0.0 45.1 7.5 13.0 28.0 22.7 16.7 
13 CW8-IM 0.0 44.7 7.4 13.0 27.6 22.4 16.7 
16 CW9 0.2 46.7 6.9 12.4 23.8 18.5 13.3 
16 CW9-IM 0.2 46.3 7.0 12.5 23.5 18.6  13.6 
AVG BECT 0.1 45.7 7.5 12.9 26.7 21.2 15.4 
σ BECT 0.1 2.6 1.2 1.5 3.8 3.4 2.8 
AVG IM-BECT 0.1 44.8 7.4 12.7 26.1 20.8 15.3 
σ IM-BECT 0.1 3.0 1.1 1.5 3.4 3.0 2.6 
Change* 0.0 -0.9 -0.1 -0.2 -0.6 -0.4 -0.1 
*Note CWX and CWX-IM indicate BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Change equals AVG IM-BECT – AVG BECT, where AVG BECT and AVG IM-BECT are 
metric averages for BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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changes in the average heart: V5Gy, V10Gy, V22.5Gy, and V30Gy for IM-BECT+IMXT relative to 
BECT+IMXT were -1.0%, 1.0, -0.6, and -0.2%, respectively, showing that on average the use of 
IM-BECT did not pose any additional cardiac risk. CW7 had an increase in V22.5Gy and V30Gy of 
1.6 and 1.3%, respectively, with the IM-BECT+IMXT plan. For this patient the heart Dmean of 
8.3 Gy with IM-BECT+IMXT compared to 7.6 Gy with BECT+IMXT, exceeded the potential 
Table 3.8 Heart Dmin, Dmax, Dmean, SD, V5Gy, V10Gy, V22.5Gy, and V30Gy 
 Heart 
e- 
Energy 
Patient 
-Plan 
Dmin Dmax Dmean SD V5Gy V10Gy V22.5Gy V30Gy 
[MeV] [Gy] [Gy] [Gy] [Gy] [%] [%] [%] [Gy] 
16 CW1 1.1 27.0 5.9 7.0 31.6 20.1 4.9 0.8 
16 CW1-IM 1.2 28.0 5.3 6.2 28.7 17.4 3.1 0.2 
13 CW2 0.7 29.0 3.7 5.7 19.8 12.1 2.5 0.2 
13 CW2-IM 0.8 30.0 3.7 5.6 19.5 11.9 2.3 0.2 
13 CW3 0.8 31.0 4.9 7.2 25.6 16.8 5.1 1.2 
13 CW3-IM 0.8 32.0 4.2 6.2 22.2 13.8 3.2 0.3 
16 CW4 0.8 33.0 3.0 3.8 13.1 6.0 0.6 0.0 
16 CW4-IM 0.9 34.0 2.9 3.6 11.9 5.5 0.5 0.0 
16 CW5 0.7 35.0 4.7 6.8 24.2 15.2 4.3 1.0 
16 CW5-IM 0.8 36.0 4.5 6.4 23.0 14.2 3.8 0.8 
13 CW6 0.8 37.0 6.0 8.6 29.2 20.0 7.7 3.4 
13 CW6-IM 0.8 38.0 5.4 7.8 27.2 18.1 6.1 2.2 
16 CW7 1.1 39.0 7.6 9.0 37.7 25.8 10.8 3.7 
16 CW7-IM 1.2 40.0 8.3 9.5 39.9 28.0 12.4 5.0 
13 CW8 0.6 41.0 3.8 6.2 20.4 12.8 3.0 0.5 
13 CW8-IM 0.6 42.0 3.9 6.3 20.5 13.0 3.2 0.5 
16 CW9 1.2 43.0 5.4 6.2 30.2 17.5 3.1 0.3 
16 CW9-IM 1.3 44.0 5.2 5.8 28.9 16.1 2.3 0.2 
AVG BECT 0.9 35.0 5.0 6.7 25.7 16.3 4.7 1.2 
σ BECT 0.2 5.5 1.4 1.5 7.4 5.7 3.0 1.4 
AVG IM-BECT 0.9 36.0 4.8 6.4 24.7 15.3 4.1 1.0 
σ IM-BECT 0.2 5.5 1.5 1.6 7.8 6.0 3.4 1.6 
Change* 0.0 1.0 -0.2 -0.3 -1.0 -1.0 -0.6 -0.2 
*Note CWX and CWX-IM indicate BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Change equals AVG IM-BECT – AVG BECT, where AVG BECT and AVG IM-BECT are 
metric averages for BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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clinical acceptability limit of 8 Gy. For all 16 MeV plans, the average Heart-Dmean was 5.3 Gy 
±1.7 Gy compared to an average 4.5 Gy ±0.9 Gy for all 13 MeV plans.  
3.4.4 Contralateral Breast Metrics 
The average contralateral breast: Dmin, Dmax, and Dmean dose for BECT+IMXT plans were 
0, 17.9, and 1.3 Gy compared to 0, 16.1, and 1.2 Gy for the IM-BECT+IMXT plans. The 
changes in the average contralateral breast: Dmin, Dmax, and Dmean doses for IM-BECT+IMXT 
plans relative to those for BECT+IMXT plans was 0.1, -1.8, and -0.1 Gy. Table 3.9 lists the 
contralateral breast: Dmean, SD, and V5Gy for each plan. The change in the average contralateral 
breast V5Gy for IM-BECT+IMXT relative to BECT+IMXT was -0.6%. 
3.4.5  Biological Metrics 
 The biological metrics of TCP, NTCP, and SCCP are tabulated in Table 3.10. All patients 
showed a slight reduction in TCP for the PTV and e-Target, except for the PTV-TCP for CW5 
and CW9. Although the average change in PTV and e-Target TCP with IM-BECT+IMXT 
relative to BECT+IMXT were each -0.1%, all TCP were at least 99.0%. These small differences 
in TCP are not clinically significant. 
Average lung NTCP was 2.1% with BECT+IMXT and did not change with IM-
BECT+IMXT. Average heart and myocardium NTCP were 0.2% and 0.3% with BECT+IMXT. 
There was no change in heart NTCP with IM-BECT+IMXT, but average myocardium NTCP fell 
by 0.1%. 
Average Lung SCCPle, which was calculated using a linear-exponential dose response 
model, was 2.3% with BECT+IMXT and did not change with IM-BECT+IMXT, however 
average Lung SCCPl, which was calculated using a linear model, was 12.6% with BECT+IMXT 
and was reduced to an average of 12.4% with IM-BECT+IMXT.  Average contralateral breast  
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SCCPle was 0.4% with BECT+IMXT and did not change with IM-BECT+IMXT, however 
average contralateral breast SCCPl, was 1.0% with BECT+IMXT and was reduced to an average 
of 0.9% with IM-BECT+IMXT.  
  
Table 3.9 Contralateral Breast Dmin, Dmax, Dmean, SD, and V5Gy 
  Contralateral Breast 
e- 
Energy 
Patient 
-Plan 
Dmin Dmax Dmean SD V5Gy 
[MeV] [Gy] [Gy] [Gy] [Gy] [%] 
16 CW1 0.0 20.8 1.5 4.6 7.3 
16 CW1-IM 0.0 15.4 1.1 3.6 5.4 
13 CW2 0.0 11.3 0.8 3.0 3.6 
13 CW2-IM 0.0 10.6 0.8 2.9 3.4 
13 CW3 0.0 15.8 1.0 4.1 4.1 
13 CW3-IM 0.0 10.8 0.8 3.3 3.2 
16 CW4 0.1 21.6 1.3 4.7 5.1 
16 CW4-IM 0.1 20.2 1.3 4.4 4.9 
16 CW5 0.0 10.4 0.8 2.7 3.6 
16 CW5-IM 0.0 8.8 0.7 2.4 3.1 
13 CW6 0.0 33.8 2.2 7.2 8.2 
13 CW6-IM 0.0 31.3 1.9 6.7 7.4 
16 CW7 0.0 11.4 1.0 3.5 3.7 
16 CW7-IM 0.0 12.9 1.0 3.8 4.0 
13 CW8 0.0 5.4 0.5 1.6 2.2 
13 CW8-IM 0.0 5.6 0.5 1.7 2.2 
16 CW9 0.1 30.9 2.7 6.9 11.7 
16 CW9-IM 0.1 29.6 2.5 6.6 10.9 
AVG BECT 0.0 17.9 1.3 4.3 5.5 
σ BECT 0.0 9.7 0.7 1.9 3.0 
AVG IM-BECT 0.0 16.1 1.2 3.9 4.9 
σ IM-BECT 0.1 9.1 0.6 1.7 2.7 
Change* 0.0 -1.8 -0.1 -0.4 -0.6 
*Note CWX and CWX-IM indicate BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Change equals AVG IM-BECT – AVG BECT, where AVG BECT and AVG IM-BECT are 
metric averages for BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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3.5  Discussion and Conclusion 
 
In Aim 2, BECT+IMXT and IM-BECT+IMXT treatment plans were generated for the 
remaining six patients using the strategy developed in Aim 1, and for all patients, dose metrics 
Table 3.10 Biological metrics for TCP, NTCP, and SCCP 
 PTV e-Target Total Lung Heart Myo-
cardium 
Contralateral 
Breast 
Patient 
-Plan 
TCP TCP NTCP SCCPle SCCPl NTCP NTCP SCCPle SCCPl 
[%]  [%] [%] [%] [%] [%] [%] [%] [%] 
CW1 99.9 99.9 2.2 2.4 13.0 0.2 0.2 0.5 1.2 
CW1-IM 99.8 99.8 2.1 2.4 12.8 0.1 0.1 0.4 0.9 
CW2 100.0 100.0 1.7 2.1 10.8 0.1 0.1 0.3 0.7 
CW2-IM 99.9 99.9 1.6 2.1 10.6 0.1 0.1 0.3 0.6 
CW3 100.0 100.0 3.0 2.3 15.5 0.2 0.2 0.3 0.8 
CW3-IM 99.7 99.8 2.5 2.3 14.0 0.1 0.1 0.3 0.6 
CW4 99.1 99.6 1.2 2.3 8.7 0.0 0.0 0.4 1.0 
CW4-IM 99.0 99.5 1.2 2.3 8.5 0.0 0.0 0.4 1.0 
CW5 99.7 100.0 2.5 2.4 13.9 0.2 0.3 0.3 0.6 
CW5-IM 99.9 100.0 2.4 2.4 13.7 0.1 0.2 0.3 0.5 
CW6 99.9 100.0 2.8 2.1 15.0 0.5 0.7 0.4 1.7 
CW6-IM 99.9 99.9 2.7 2.1 14.6 0.3 0.4 0.4 1.5 
CW7 99.9 100.0 2.0 2.5 12.5 0.5 0.7 0.4 0.7 
CW7-IM 99.9 99.9 2.2 2.6 12.9 0.7 1.0 0.4 0.8 
CW8 99.7 100.0 2.1 2.0 12.6 0.1 0.1 0.3 0.4 
CW8-IM 99.6 100.0 2.1 2.0 12.5 0.1 0.1 0.3 0.4 
CW9 99.9 99.9 1.8 2.4 11.5 0.1 0.1 0.7 2.1 
CW9-IM 99.9 99.9 1.9 2.5 11.7 0.1 0.1 0.7 2.0 
AVG 99.8 99.9 2.1 2.3 12.6 0.2 0.3 0.4 1.0 
 σ 0.3 0.1 0.6 0.2 2.1 0.2 0.3 0.1 0.6 
AVG-IM 99.7 99.8 2.1 2.3 12.4 0.2 0.2 0.4 0.9 
 σ-IM 0.3 0.2 0.5 0.2 1.9 0.2 0.3 0.1 0.5 
Change* -0.1 -0.1 0.0 0.0 -0.2 0.0 -0.1 0.0 -0.1 
*Note CWX and CWX-IM indicate BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Change equals AVG IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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were calculated for the lower-left CW electron PTV subtarget (i.e. the e-Target), the PTV, and 
specific OARS, as well as biological metrics (TCP, NTCP, and SCCP).  
For five of the six Aim 2 patients (i.e. all except, CW8), BECT+IMXT and IM-
BECT+IMXT coverage of the PTV superior to the superior extent of the heart could not be 
achieved with 13 MeV electrons. For these patients, the next available higher electron energy, 16 
MeV was sufficient. One patient plan, CW7 IM-BECT+IMXT, failed to meet the Heart-Dmean < 
8 Gy criteria for potential clinical acceptability, although the difference from 8.0 Gy is not 
considered clinically significant. 
Chen et al. have demonstrated that higher PTV-V107% and TV-V110% are associated with 
increased incidence of acute radiation dermatitis (Chen 2010). PTV and e-Target V107% and 
V110% were calculated to compare the changes PTV-V107% and TV-V110% volumes separately. In 
the e-Target, where the largest changes are expected, the average V107% and V110% were reduced 
from 10.6% to 2.2% and 2.9% to 0.2%, respectively. It is worth noting that the difference for a 
single patient can be much pronounced. For example, in the e-Target for CW4, CW5, and CW7, 
all treated with 16 MeV, the inclusion of intensity modulation reduced the V107 from 28.6%, 
11.8%, and 17.42% to 1.1%, 1.0%, and 0.5%, respectively, and the V110 from 9.9%, 4.4%, and 
5.0% to 0.0%, 0.0%, and 0.0%, respectively. 
In terms of OARs metrics, the most clinically significant improvements were in average 
Lung-Dmax and Contralateral Breast-V5Gy metrics. With IM-BECT+IMXT, the Lung-Dmax and 
Contralateral Breast-V5Gy were reduced from 45.7 to 44.8 Gy, respectively, and 5.5% to 4.9%, 
respectively. On average, heart and myocardium plan metrics showed no significant difference of 
clinical importance for IM-BECT+IMXT compared to BECT+IMXT. Likewise, there were no 
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clinically significant differences in in calculated biological metrics for the OARs, with the 
maximum difference being found for Lung-SCCPl (-0.2% change with IM-BECT+IMXT). 
In conclusion, there were no clinically significant detriments to the PTV or OAR plan 
metrics using IM-BECT+IMXT. There were however, non-negligible benefits to dose 
homogeneity within the e-Target, most notably in terms of reduced average V107%.for patients at 
16 MeV. These findings suggest that the overall benefit of IM-BECT will be directly correlated 
to the relative portion of the PTV that is being treated with electrons for mixed-beam treatments. 
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Chapter 4. Aim 3 – Test for Statistical Significance 
 
 Comparisons of the averages of treatment plan metrics, (Aim 2), have revealed some 
potential benefits of the IM-BECT+IMXT technique.  Testing the hypothesis that IM-
BECT+IMXT plans are superior to BECT+IMXT plans, however, requires consideration of both 
the magnitude and statistical significance of each of the benefits and drawbacks. The following 
statistical analysis of the distributions of patient-specific metric differences has been performed 
to determine if the observed benefits are significant findings. 
4.1 Statistical Methods 
 
The primary assumption regarding the paired treatment plan metrics, i.e. the 
BECT+IMXT set and the IM-BECT+IMXT set, was that the distribution of data for all metrics 
in both sets are non-parametric. In other words, for both treatment techniques, the repeated 
measures of each metric for all nine patients studied were not drawn from normal Gaussian 
distributions. Under this assumption, a two-tailed Wilcoxon signed rank statistical test may be 
used to compare the two techniques based on the repeated measures of the plan metrics (Chaikh 
2014). Matlab’s Statistics and Machine Learning Toolbox was used to perform the statistical 
analysis, for which p-value ≤ 0.05 was considered significant. 
4.2 Results of Statistical Analysis 
 
4.2.1 PTV and e-Target Metrics 
Table 4.1 shows the p-value determined by the Wilcoxon signed rank test in comparisons 
of PTV Dmin, Dmax, Dmean, D95%, V95%, CI, and TV-V110% metrics from BECT+IMXT and IM-
BECT+IMXT treatment plans. The table also lists the average metric values for each plan type 
and the change due to the use of IM-BECT+IMXT. None of the differences in PTV metrics in 
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Table 4.1 are clinically significant. The only PTV metric that was determined to be statistically 
different was Dmin (p = 0.012, -0.3 Gy change). Dmax (p=0.55) was marginally significant. None 
of the other PTV metrics in Table 4.1 are clinically significant changes with the IM-
BECT+IMXT technique.  
Table 4.2 lists the average values, differences, and p-values for PTV and e-Target 
metrics: V107%, V110%, DHI, and dDVH FWHM.  When calculated for the e-Target separately 
V107% (p=0.004, -8.4% change), V110% (p=0.004, -2.7% change), and FWHM (p=0.004, -2.0 Gy 
Table 4.1 PTV Dmin, Dmax, Dmean, D95%, V95%, and CI; and TV-V110% 
 PTV TV 
 Dmin Dmax Dmean D95% V95% CI V110% 
 [Gy] [Gy] [Gy] [Gy] [%]  [%] 
AVG* 46.0 54.4 50.5 47.5 95.0 0.344 3.3 
AVG-IM* 45.7 53.7 50.4 47.5 95.0 0.345 2.6 
Change* 
-0.3 -0.7 -0.1 0.0 0.0 0.001 -0.7 
p-value 0.012 0.055 0.570 0.551 0.363 0.602 0.820 
 
*Change equals AVG-IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Table 4.2 PTV and e-Target V107%, V110%, DHI, and FWHM 
 PTV e-Target 
 V107% V110% DHI FWHM V107% V110% DHI FWHM 
  [%] [%]  [Gy] [%] [%]  [Gy] 
AVG* 6.0 1.3 0.167 2.8 10.6 2.9 0.200 4.2 
AVG-IM* 3.3 0.3 0.161 3.0 2.2 0.2 0.180 2.2 
Change 
-2.7 -1.0 -0.006 0.2 -8.4 -2.7 -0.020 -2.0 
p-value 0.074 0.098 0.570 0.301 0.004 0.004 0.074 0.004 
 
*Change equals AVG-IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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change) were each statistically significantly decreased, indicative of a potential benefit to e-
Target dose homogeneity using IM-BECT compared to BECT. These differences impacted the 
total PTV but not enough to make a highly significant difference, i.e. p=0.074 and p=0.095 for 
PTV V107% and V110%, respectively. 
4.2.2 Lung 
Table 4.3 lists the average values, differences, and p-values for Lung Dmin, Dmax, Dmean, V5Gy, 
V10Gy, and V20Gy for BECT+IMXT and IM-BECT+IMXT plans.  Among these, only lung Dmax 
was statistically significantly different with use of IM-BECT+IMXT (p=0.004, -0.9 Gy change). 
However, this reduction in lung Dmax may not be clinically significant.  
4.2.3 Heart  
Table 4.4 lists the average values, differences, and p-values for Heart Dmin, Dmax, Dmean, 
V5Gy, V10Gy, and V22.5Gy, and V30Gy for BECT+IMXT and IM-BECT+IMXT plans. Among these, 
only Heart Dmin (p=0.004, < .05 Gy change) was found to be statistically different, though the 
magnitude of the difference, < .05 Gy, should be clinically insignificant. 
Table 4.3 Lung Dmin, Dmax, Dmean, V5Gy, V10Gy, and V20Gy 
 Lung 
 Dmin  Dmax  Dmean  V5Gy V10Gy  V20Gy  
  [Gy] [Gy] [Gy]  [%] [%] [%] 
AVG* 0.1 45.7 7.5 26.7 21.2 15.4 
AVG-IM* 0.1 44.8 7.4 26.1 20.8 15.3 
Change* 0.0 -0.9 -0.1 -0.6 -0.4 -0.1 
p-value 1.000 0.004 0.156 0.074 0.164 1.000 
 
*Change equals AVG-IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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4.2.4 Contralateral Breast  
Table 4.5 lists the average values, differences, and p-values for contralateral breast Dmin, 
Dmax, Dmean, and V5Gy for BECT+IMXT and IM-BECT+IMXT plans. Among these, only 
Contralateral Breast V5Gy (p=0.004, -0.6% change) was found to be statistically significantly 
different and may have potential clinical significance.  
Table 4.5 Contralateral Breast Dmin, Dmax, Dmean, and V5% 
 Contralateral Breast 
  Dmin Dmax Dmean V5% 
 [Gy] [Gy] [Gy] [%] 
AVG* 0.0 17.9 1.3 5.5 
AVG-IM* 0.1 16.1 1.2 4.9 
Change* 0.1 -1.8 -0.1 -0.6 
p-value 1.000 0.055 0.051 0.039 
 
*Change equals AVG-IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
Table 4.4 Heart Dmin, Dmax, Dmean, V5%, V10%, V22.5%, and V30% 
 Heart 
  Dmin Dmax Dmean V5% V10% V22.5% V30% 
 [Gy] [Gy] [Gy] [%] [%] [%] [%] 
AVG* 0.9 26.5 5.0 25.7 16.3 4.7 1.2 
AVG-IM* 0.9 25.4 4.8 24.7 15.3 4.1 1.0 
Change* 0.0 -1.1 -0.2 -1.0 -1.0 -0.6 -0.2 
p-value 0.004 0.098 0.203 0.098 0.098 0.164 0.250 
 
*Change equals AVG-IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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4.2.5 Biological metrics  
Table 4.6 lists the average values, differences, and p-values for the biological metrics of 
TCP, NTCP, and SCCP for BECT+IMXT and IM-BECT+IMXT plans
. 
 Among these, only TCP 
and Contralateral Breast SCCP showed statistically significant differences, with Contralateral 
Breast SCCPl (p=0.043, -0.1% change) being marginally reduced with IM-BECT+IMXT. 
Statistical analysis for TCP was performed separately for PTV and e-Target volumes, revealing 
only a slight statistically, but non-clinically, significant reduction of e-Target TCP (p=.004, -
0.1% change) with IM-BECT+IMXT compared to BECT+IMXT. 
 
4.3 Discussion & Conclusion 
 
For the sample of nine post mastectomy chest wall patients, plan metrics for the PTV, e-
Target, lung, heart, and contralateral breast, as well as biological metrics of TCP, NTCP, and 
SCCP have been analyzed to determine if there is statistically significant difference between 
treatment plans for IM-BECT+IMXT and BECT+IMXT. The only statistically and potentially 
Table 4.6 Biological metrics for TCP, NTCP, and SCCP 
 PTV e-Target Total Lung Heart Myo- 
cardium 
Contralateral 
Breast 
 TCP TCP NTCP SCCPle SCCPl NTCP NTCP SCCPle SCCPl 
[%] [%] [%] [%] [%] [%] [%] [%] [%] 
AVG* 99.8 99.9 2.1 2.3 12.6 0.2 0.3 0.4 1.0 
AVG-IM* 99.7 99.8 2.1 2.3 12.4 0.2 0.2 0.4 0.9 
Change* 
-0.1 -0.1 0.0 0.0 -0.2 0.0 -0.1 0.0 -0.1 
p-value 0.133 0.004 0.176 0.625 0.164 0.234 0.375 0.656 0.043 
 
*Change equals AVG-IM – AVG, where AVG and AVG-IM are metric averages for 
BECT+IMXT and IM-BECT+IMXT plans, respectively. 
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clinically significant differences were benefits of IM-BECT+IMXT for the e-Target, lung, and 
contralateral breast. There were no statistically and clinically significant differences among the 
biological metrics. 
 For the e-Target, the primary benefit with IM-BECT comes in the form of increased dose 
homogeneity as expected. The statistically significant differences in V107% (p=0.004) and V110%, 
(p=0.004) are potentially clinically significant benefits, especially for cases where the e-target is 
a larger portion of the PTV. On average IM-BECT+IMXT reduced the V107% and V110% from 
10.6% (±8.4%) to 2.2% (±2.8%), respectively, and 2.9% (±3.2%) to 0.2% (±0.3%), respectively. 
The statistically significant differences in Lung-Dmax (p=0.004) and Contralateral Breast-V5Gy 
(p=0.039) could have minor biological effect and clinical significance due to the magnitudes of 
their reductions with IM-BECT+IMXT on average (-0.9 Gy and 0.6%, respectively). 
Overall the use of IM-BECT has a small but potentially clinically significant advantage 
over BECT without intensity modulation. Post mastectomy patients whose anatomy allows for a 
larger volume of the PTV treated with electrons could show increased benefit from the use of 
intensity modulation. To a lesser extent than VMAT, IM-BECT+IMXT can improve the level of 
dose homogeneity (i.e. reduce volume of high dose) within the PTV compared to BECT+IMXT. 
However, VMAT delivers higher NCTP and SCCP for critical organs such as the heart, lung, and 
contralateral breast.  
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Chapter 5. Conclusions 
 
5.1 Summary of Results 
 
IM-BECT has previously been shown to restore dose homogeneity to BECT 
(Kudchadker 2002), however, the clinical significance of improved BECT dose homogeneity in 
the PMRT setting has not. Thus, the goal of this research was to evaluate the benefit of including 
IM for BECT in PMRT treatment plans. This work evaluated the potential clinical significance 
of IM-BECT using a treatment planning study comprised of nine left-side PMRT patients. The 
study compared dose metrics predicted treatment outcomes of treatment plans using BECT and 
parallel opposed IMXT tangents to treat inferior CW and remaining superior PTV, respectively, 
with that using IM-BECT in lieu of BECT. A strategy to generate the IM-BECT+IMXT and 
BECT+IMXT treatment plans, which was developed using a test set of three patients (Aim 1), 
was subsequently used to plan the remainder (Aim 2). For the sample of nine patients, plan 
metrics for the PTV, e-Target, lung, heart, and contralateral breast, as well as biological metrics 
(TCP, NTCP, and SCCP), were calculated (Aim 2) and analyzed to determine if there is 
statistically significant difference between treatment plans for IM-BECT+IMXT and 
BECT+IMXT (Aim 3). The hypothesis was that the IM-BECT+IMXT plans would be 
statistically superior to plans using BECT+IMXT. 
5.1.1 Results of Aim 1 
 
The treatment planning strategy summarized below was able to generate potentially 
clinically acceptable plans based on the criteria given in Section 2.1.10:  
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1) Selection of electron energy and beam geometry at 105 cm SSD (e.g. gantry angle 
and field size) such that coverage of a portion of the PTV with 47.5 Gy (95% 
prescribed dose) is possible superior to the superior extent of the heart.     
2) Selection of parallel opposed 6MV-RAO and 10MV-LPO x-ray beam geometries 
such that their inferior and medial beam sides are HBB, and the inferior beam sides 
are parallel to the superior electron beam side with a 1.5 cm overlap. 
3) Segmentation of the PTV into an inferior e-Target (i.e. the target to be treated with  
BECT or IM-BECT), a JCT region (i.e. a 3 cm field junction region of the PTV 
superior to the e-Target to be treated by optimizing the IMXT fields on top of the 
BECT or IM-BECT dose distributions), and a superior γ-Target (i.e. the remainder of 
the PTV to be treated with IMXT). 
4) Design of patient-specific bolus for BECT or IM-BECT by applying bolus design 
operator sequences (Section 2.1.6.2) shown to yield acceptable dose distributions for 
13 and 16 MeV electron beams. MU were selected to deliver 50 Gy (90% given 
dose). 
5) Optimization of tangent parallel opposed IMXT beams to improve dose uniformity in 
the JCT and coverage of the γ-Target in a region of varying patient thickness. Mu 
were selected to deliver 50 Gy. 
6) Plan normalization after IMXT optimization to achieve 95% PTV coverage with 95% 
of the prescribed dose. 
 
An electron energy study, which compared BECT+IMXT and IM-BECT+IMXT plans at 
13, 16, and 20 MeV, determined no lung benefit with increased electron energy, and the 
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according gain in superior BECT or IM-BECT PTV coverage. Thus, the treatment planning 
strategy uses the minimum electron energy required to achieve BECT or IM-BECT coverage of 
the PTV to no less than the superior extent of the heart.  
5.1.2 Results of Aims 2 & 3 
 
For five of the six Aim 2 patients, BECT+IMXT and IM-BECT+IMXT coverage of the PTV 
superior to the superior extent of the heart could not be achieved with 13 MeV electrons. For 
these patients, the next available higher electron energy, 16 MeV was sufficient. One 16 MeV 
plan (CW7-IM), however marginally failed to meet the Heart-Dmean < 8 Gy criteria (8.3 Gy).  
Overall, IM-BECT had small but potential clinically significant advantages over BECT 
without intensity modulation. For the sample of nine patients, there were statistically and 
potentially clinically significant benefits of IM-BECT+IMXT for the e-Target, lung, and 
contralateral breast. The statistically significant differences in average Lung-Dmax (p=0.004) and 
Contralateral Breast-V5Gy (p=0.039) are potentially minimally clinically significant due to the 
magnitudes of their reductions (-0.9 Gy and 0.6%, respectively.) The primary benefit for the e-
Target comes in the form of statistically significantly reduced V107% (p=0.004) and V110%, 
(p=0.004), which on average were reduced from 10.6% to 2.2%, respectively, and 2.9% to 0.2%, 
respectively. This was expected based on the previous study of Kudchadker et al. (2002). 
The hypothesis of this work is supported by the results showing statistically significant 
improvements in plan metrics with IM-BECT—sans any clinically significant drawbacks. Post 
mastectomy patients whose anatomy allows for a larger volume of the PTV treated with 
electrons, could benefit more from the improved dose homogeneity with the use of intensity 
modulation. However, only a single BECT+IMXT patient plan surpassed the TV-V110% 
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associated with higher incidence of acute skin toxicity
 
(5.3% (Chen 2010)). This suggests the use 
of IM-BECT may only be necessary for some patients in the setting of PMRT. 
5.2 Recommendations for Future Work 
 
The future work relating to this study of IM-BECT for PMRT should focus on the 
following areas: 
1. The IM Operator: Though the simplistic methodology of the intensity modulation 
operator used in the work led to reasonable improvements in dose homogeneity, it has 
limitations due to the effects of MCS. A more sophisticated forward planning 
operator or inverse optimization of intensity modulation, such as that proposed by 
Chambers (2016), merits future work.   
2. Extension of IM: Using the current research version of p.d, extension of pencil beam 
weights from the target inner margin to the electron beam edge in the field junction 
may have contributed to less dose uniformity in the field junction region using IM-
BECT+IMXT compared to BECT+IMXT. Further analysis of this effect, and a 
possible solution using IM-BECT to preferentially broaden the electron penumbra in 
the field junction may benefit dose uniformity.   
3. Motion Evaluation: The breath hold technique is currently in use for left sided breast 
RT at MBP, and as so, dose uncertainty due to bolus position as a result of chest wall 
motion during respiration will be of interest in validating the delivery of PMRT with 
IM-BECT.  
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Appendix A. DVH and Isodose Plots 
 
Contents: 
 
CW1-16 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.1 CW1-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target.  
Figure A.2 CW1-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT.  
Figure A.3 CW1-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT.  
Figure A.4 CW1-16 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.5 CW1-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT.  
Figure A.6 CW1-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
 
CW2-13 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.7 CW2-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.8 CW2-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT.  
Figure A.9 CW2-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT.  
Figure A.10 CW2-13 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.11 CW2-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target and 
the JCT. 
Figure A.12 CW2-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
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CW3-13 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.13 CW3-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.14 CW3-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.15 CW3-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT.  
Figure A.16 CW3-13 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice.  
Figure A.17 CW3-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target and 
the JCT. 
Figure A.18 CW3-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
 
CW4-16 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.19 CW4-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.20 CW4-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.21 CW4-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.22 CW4-16 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.23 CW4-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target and 
the JCT. 
Figure A.24 CW4-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
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CW5-16 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.25 CW5-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.26 CW5-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.27 CW5-16 MeV BECT+IMXT: Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.28 CW5-16 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.29 CW5-16 MeV IM-BECT+IMXT: Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.30 CW5-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
 
CW6-13 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.31 CW6-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.32 CW6-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.33 CW6-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.34 CW6-13 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.35 CW6-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target and 
the JCT. 
Figure A.36 CW6-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
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CW7-16 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.37 CW7-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.38 CW7-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.39 CW7-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.40 CW7-16 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.41 CW7-16 MeV IM-BECT+IMXT: Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.42 CW7-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
 
CW8-13 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.43 CW8-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.44 CW8-13 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.45 CW8-13 MeV BECT+IMXT: Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.46 CW8-13 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.47 CW8-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target and 
the JCT. 
Figure A.48 CW8-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice. 
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CW9-16 MeV, BECT+IMXT and IM-BECT+IMXT plans: 
Figure A.49 CW9-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for PTV, esophagus, total 
lung, heart, contralateral breast, contralateral lung, spinal cord, and e-Target. 
Figure A.50 CW9-16 MeV BECT+IMXT and IM-BECT+IMXT DVH for the γ-Target and the 
JCT. 
Figure A.51 CW9-16 MeV BECT+IMXT: Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.52 CW9-16 MeV BECT+IMXT: Transverse CT slice through the e-Target and sagittal 
CT slice. 
Figure A.53 CW9-16 MeV IM-BECT+IMXT: Transverse CT slices through the γ-Target and the 
JCT. 
Figure A.54 CW9-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target and 
sagittal CT slice.   
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Figure A.1 CW1-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.2 CW1-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.3 CW1-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.4 CW1-16 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) and 
sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.5 CW1-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.6 CW1-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.7 CW2-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.8 CW2-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
129 
 
 
Figure A.9 CW2-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.10 CW2-13 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.11 CW2-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.12 CW2-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.13 CW3-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.14 CW3-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
135 
 
 
Figure A.15 CW3-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.16 CW3-13 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.17 CW3-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.18 CW3-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.19 CW4-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.20 CW4-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.21 CW4-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.22 CW4-16 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.23 CW4-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.24 CW4-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.25 CW5-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.26 CW5-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.27 CW5-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.28 CW5-16 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.29 CW5-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
150 
 
  
Figure A.30 CW5-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-
Target (top) and sagittal CT slice through the heart (bottom) showing the PTV (red) 
with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.31 CW6-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.32 CW6-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.33 CW6-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.34 CW6-13 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.35 CW6-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.36 CW6-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.37 CW7-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.38 CW7-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.39 CW7-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.40 CW7-16 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.41 CW7-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.42 CW7-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.43 CW8-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.44 CW8-13 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.45 CW8-13 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing through PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.46 CW8-13 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.47 CW8-13 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing through PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 
40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.48 CW8-13 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.49 CW9-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for PTV evaluate (red), esophagus (orange), total lung (blue, upper plot), heart 
(pink), contralateral breast (forest green), contralateral lung (yellow), spinal cord (cyan), and 
e-Target (blue, lower plot). 
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Figure A.50 CW9-16 MeV BECT+IMXT (solid lines) and IM-BECT+IMXT (dashed lines) 
DVH shown for the γ-Target (red) and JCT (green). 
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Figure A.51 CW9-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 
15.0, and 5.0 [Gy] IDL. 
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Figure A.52 CW9-16 MeV BECT+IMXT: Transverse CT slice through the e-Target 
(top) and sagittal CT slice through the heart (bottom) showing the PTV (red) with 
57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.53 CW9-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target 
(top) and JCT (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 50.0, 47.5, 45.0, 40.0, 
30.0, 15.0, and 5.0 [Gy] IDL. 
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Figure A.54 CW9-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice through the heart (bottom) showing the PTV (red) with 57.5, 55.0, 52.5, 
50.0, 47.5, 45.0, 40.0, 30.0, 15.0, and 5.0 [Gy] IDL. 
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Appendix B. p.d Code Corrections; May 16, 2017 report to .decimal, LLC. 
 
This study required extensive use of BolusECT® software in .decimal, LLC’s p.d planning 
system. During its use in the thesis research, several errors and inconsistencies were discovered. 
Each problem was reported to my advisor (Carver) and project director (Hogstrom) for further 
analysis and a solution (code fix), which in many cases, was implemented into the research 
version of the software for immediate use. These problems and solutions were reported to 
.decimal, LLC. (Erhart-Chief Software Developer) for potential implementation into a future p.d 
release. This was a major contribution of the thesis research, and below is a report on the 
problems and solutions provided to .decimal, LLC. 
 
Bobby Carver, PhD, Kenneth Hogstrom, PhD, John Doiron, B.Sc. 
 
Contents: 
 
1. Target Inner Margin 
2. Pencil Beam Size 
3. DICOM export 
4. Extended SSD Air Gap Factor 
5. Smoothing 
6. Isodose Operator where no 90% exists 
7. Surface Dose 
8. Specified Shift 
9. Bolus Extension Operator 
10. Density Override Order 
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1. Target Inner Margin:  
 Problem: 
• During the utilization of p.d operators for bolus design (creation, modification, 
and intensity modulation), we observed that these operators were not being 
limited to the PTV less bolus inner margin. Some operators appeared to 
encompass the entire surface of the bolus (i.e. field plus block outer margin).   
• If the inner margin was changed even slightly (e.g. from 1.0 to 1.01) p.d would 
yield dramatically different results. The program appeared to be adding to the 
previous inner margin, i.e. instead of the inner margin becoming 1.01 it became 
2.01. 
Analysis: 
• p.d was defining the entire PTV as the inner margin, which caused problems with 
the isodose shift operator.  
• There were also two different implementations in the extension operator for 
defining the inner margin, depending on if the inner margin had changed from 
previous operators. For example, a Create with 0.5cm IM followed by an Isodose 
shift with 0.5cm inner margin yielded dramatically different results than a Create 
with 0.5cm inner margin followed by an Isodose shift with 0.51 inner margin.  
Fix: 
The code’s region definitions were modified, and a fourth region was added that 
defines the inner margin: 
0 = Outside the field 
1 = Inside the field 
2 = Inside the target 
3 = Inside the target inner margin (added for Research Version) 
 
In conjunction with the new region definitions, the portion of the extension 
operator code that previously had two implementations for defining the inner margin was 
modified and consolidated to one implementation, not dependent on if the inner margin 
has changed.  
 
2. Pencil Beam Size:  
Analysis: 
 p.d was defining the pencil beam size based on the field size and energy, while 
maintaining the 2.5 ratio of depth to width (note: when changing pencil beam size, the 
energy bin width should also be adjusted accordingly, which was not done here). This can 
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cause protracted dose calculation times and possibly impacted the surface dose 
calculation. 
 Fix: 
 The pencil beams have been defined to be 2mm x 2mm x 5 mm.  Low Priority: 
Before implementing a variable pencil beam size, a comprehensive study of the effects on 
resulting dose distributions is needed. 
 
3. DICOM Export:  
 Problem: 
We observed that the 50% isodose line (near R100) displayed in Pinnacle disagreed 
with that shown in p.d. This difference was observed on both flat and cylindrical 
phantoms with rectangular fields. The size of the difference appears to be dependent on 
both SSD and distance off-axis. (See attached report by Doiron) 
 Fix: 
 The correct transformation from diverging to rectilinear gird was implemented. 
 
4. Extended SSD Air Gap Factor:  
 Problem: 
With chest wall patients at extended SSD there was no 100% dose value near the 
central axis as expected. This error was verified by rectangular (not half beam blocked) 
fields on flat and cylindrical phantoms. These tests confirmed that central-axis dose 
values were incorrectly too low. 
 Analysis: 
 In the DoseEngine:Output corrections subroutine p.d was dividing values of the 
final dose by the PBRA air gap factor instead of multiplying. Note, the PBRA air gap 
correction factor is defined as: 
  =	 	>?@		FGG							∗	 ¡ 
where the AGCFs were generated by PBRA CAX dose calculations in a water phantom. 
(Note: AGCF = 1/AGF) 
 Fix – Equation was fixed to multiplication in research version. 
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5. Smoothing:  
 
Problem:  
Smoothing parameters are different than those defined in Low et at. In p.d (a2)i,j is 
a2 where a is defined as the bolus surface point spacing (fine: 0.1 cm, standard: 0.2 cm, 
and coarse: 0.4 cm).  
 Fix: 
 No fix has been implemented. 
 
 
6. Isodose Operator where no 90% exists:  
 Problem: 
  Use of the isodose shift operator when no 90% line is found along a ray-line.  
 Fix: 
Three possible solutions have been proposed with the 1st currently implemented. 
Table of Low et al. and p.d Smoothing Parameters 
Parameter Low p.d Range Default 
Current Rec. Current Rec. 
µ Weighting 
Coefficient 
Same 1-100 1-10 10.0 1.0 
η Smoothing 
Radius 
Same 0.4-
100 
0.5-3.0 1.0 2.0 
a √¢g at Distal 
PTV surface 
a = Bolus 
Point Spacing 
0.1 – 
0.4 cm 
1.0 cm 0.2  
cm 
1.0 
cm 
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1. Nearest Neighbor: The bolus surface along the ray-line is defined to be at the 
height of the nearest neighbor with a 90% point. 
2. Do nothing –Make no changes to the height of the bolus along the ray-line. 
3. 90% of Max – Use the point along the ray-line that is at 90% of the ray-line’s max 
dose for isodose shift calculations. 
Note: This should not be an issue when using intensity modulation. 
7. Surface Dose:  
 Problem: 
 There were irregularities in the dose calculation (hot and cold spots as well as a 
very uneven distal 90% isodose line) apparently caused by the handling of the bolus 
surface during the dose calculation.  
 Fix:  
This problem only occurred when parts of the bolus surface extended upstream 
from isocenter (100 SSD). The problem was in the calculation of the surface level. The 
code was casting a floating-point number to the nearest integer and it should have been 
selecting the closest smaller integer. Upstream from 100 SSD the values for the surface 
position change from positive to negative causing the error when casting the floating-
point number as an integer. 
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8. Specified Shift:  
 Problem:  
The specified shift operator changed the height of the entire bolus, even outside of 
the block outer margin. When lowering the surface significant changes to the vertical 
sides of the bolus were observed. These changes appeared to change the angle of these 
sides, but had no apparent impact on dose distribution. 
 Fix: 
 In conjunction with the fix to the Target inner margin and the Extension operator 
routine, the specified shift operator now only operates within the area contained by the 
vertical sides of the bolus. The previously observed problems no longer appear. 
 
9. Bolus Extension Operator:  
 Problem: 
Code was using nearest neighbor for the entire field + block outer border. The 
extended bolus had steps which were perpendicular to the PTV less inner margin contour. 
 Fix: 
Inside the box circumscribing the PTV less inner margin contour the smaller 
bolus height between nearest neighbor and harmonic mean (Low et al. 1992) is used. 
Extension outside the circumscribing box follows procedure from Low et al. Each side of 
the box is extended to the edge of the field plus block outer border. The corners are then 
set to the value of the corner of the circumscribing box. 
 
10. Density Override Order:  
 Problem: 
When attempting to do a density override to a structure, p.d would ignore this 
override when writing the bolus values to the CT scan. This resulted in sections of 
Superflab that extended beyond the surface of the bolus begin taken to account during the 
dose calculation 
 Fix: 
The density override order was fixed so that the CT set used to write the bolus 
values was one that had already contained the user specified density overrides. 
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Appendix C. IM-BECT+IMXT & VMAT Plan Comparisons 
 
Contents: 
 
1. Sample 16 MeV IM-BECT+IMXT & VMAT Dose Plan Comparison  
2. Plan Metrics 
3. Statistical analysis 
4. Conclusion 
 
16 MeV Dose Plan Comparison (CW1) 
 Dose plans are shown Figure C.1 for the CW1 16 MeV IM-BECT+IMXT plan in 
transverse CT slices through the superior γ-Target portion of PTV and the JCT portion. The 
IMXT distribution in the γ-Target CT slice results in full PTV coverage with 95% prescribed 
dose with some areas of 52.5 Gy (105% prescribed dose) in the shallow regions of the parallel 
opposed dose distribution. In the transverse plane through the JCT there is full coverage by 95% 
prescribed dose within the field overlap region of the IM-BECT and IMXT fields.  Despite the 
use of IMXT to feather the x-ray penumbra in the field junction, there is a 55 Gy (110% 
prescribed dose) hotspot at the patient surface. 
Figure C.2 displays the dose plan for the CW1 16 MeV IM-BECT+IMXT plan within a 
transverse plane through the inferior e-Target portion of PTV and in one sagittal plane through 
the heart. The distal e-Target dose conformity is excellent except for a small cold spot in the 
lateral region of the transverse plane where the distal target lacks coverage by the 95% IDL. 
Coverage of this area would only be achieved using IM-BECT with increased electron energy. 
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Figure C.1 CW1-16 MeV BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 4500,4000, 3000, 
1500, and 500 [cGy] IDL. 
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Figure C.2 CW1-16 MeV BECT+IMXT: Transverse CT slice through the e-Target (top) and 
sagittal CT slice (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 4500,4000, 
4500,4000, 3000, 1500, and 500 [cGy] IDL. 
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Figure C.3 displays the dose plan for a CW1 6 MV VMAT plan (Heins, 2016) in 
transverse planes through γ-Target and JCT CT slices (Note: the following references to 
planning target volumes: γ-Target, JCT, and e-Target with respect to VMAT plans are strictly for 
comparing dose with IM-BECT+IMXT plans, i.e. VMAT plans did not require a field junction 
and thus had a single PTV equal to the sum of the former). The distribution in the γ-Target CT 
slice shows a highly homogeneous dose distribution using VMAT. There is also a high level of 
dose conformity to the PTV with 95% prescribed dose. However, there is a larger low dose bath 
(<5 Gy) compared to the parallel opposed IMXT arrangement in the IM-BECT+IMXT plan, 
which for the VMAT plan extends into contralateral lung. In the JCT region CT slice (referring 
to the dose plane of the VMAT plan in the same region as the abutment for the IM-BECT+IMXT 
plan) the dose is slightly less homogeneous compared to the γ-Target CT slice (small medial 
region of 105% dose within the PTV), but overall has better homogeneity and conformity than 
the IM-BECT+IMXT plan.  
Figure C.4 displays the dose plan for the CW1 6 MV VMAT plan (Heins, 2016) within a 
transverse plane through the inferior portion of the PTV and in one sagittal plane through the 
heart (same CT slices as shown for Figure C.2). The distribution in the transverse plane is 
homogeneous (only small regions of 52.5 Gy, i.e. 105% prescribed dose). Although the VMAT 
plan contains a high degree of PTV dose conformity, the 30 Gy IDL extends approximately 2 cm 
into the heart. Compared to the same transverse slice for the IM-BECT+IMXT plan, the IM-
BECT+IMXT plan 30 Gy IDL did not extend into the heart. The VMAT plan again shows a 
larger low dose bath (<5 Gy) compared to IM-BECT+IMXT, which in the sagittal plane fully 
extends to the patient surface posteroinferiorly.   
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Figure C.3 CW1-16 MeV IM-BECT+IMXT:  Transverse CT slices through the γ-Target (top) 
and JCT (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 4500,4000, 3000, 
1500, and 500 [cGy] IDL. 
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Figure C.4 CW1-16 MeV IM-BECT+IMXT: Transverse CT slice through the e-Target (top) 
and sagittal CT slice (bottom) showing PTV (red) with 5750, 5500, 5250, 5000, 4750, 
4500,4000, 3000, 1500, and 500 [cGy] IDL. 
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Dose metrics for CW1-9 
 PTV dose metrics (Dmin, Dmax, V107%, DHI, and CI; and TV-V110%) for IM-BECT+IMXT 
and VMAT plans are shown in Table C.1. The only clinically significant differences appear to be 
for average Dmin (+24.8 Gy change), average V107% (+3.3% change), average CI (-0.35 change), 
and average TV-V110% (+2.6% change) for IM-BECT+IMXT compared to VMAT. The small 
changes in average Dmax and average DHI (0.2 Gy and 0.03, respectively) are clinically 
insignificant. Comparisons of all PTV metrics except Dmin show improved plan quality with the 
use of VMAT. 
Lung dose metrics (Dmax, Dmean, SD, V5Gy, V10Gy, and V20Gy) for IM-BECT+IMXT and 
VMAT plans are shown in Table C.2. The most clinically significant change was found for the 
average Lung V20Gy (+2.3% change) with the use of IM-BECT+IMXT compared to VMAT. This 
is because a higher Lung V20Gy is associated with an increased risk of radiation pneumonitis. In 
contrast, all other average lung metrics showed an improvement with the use of IM-
BECT+IMXT compared to VMAT suggesting the degree of dose conformity across lung-PTV 
boundaries is lower for VMAT doses that are less than 20 Gy than for VMAT doses that are 
above 20 Gy. Although all lung metrics, except Lung V20Gy, show an improved plan quality with 
the use of IM-BECT+IMXT, the improvement in Lung V20Gy with VMAT is the most clinically 
significant difference.  
Heart dose metrics (Dmax, Dmean, V5Gy, V10Gy, V22.5Gy, and V30Gy) for IM-BECT and 
VMAT plans are shown in Table C.3. The most clinically significant change was found for the 
average Heart V30Gy (-4.0% change) and Dmean (-4.6 Gy change). Elevations in each of these 
metrics are associated with increased risk of cardiac complications. All Heart metrics show an 
improvement in plan quality for IM-BECT+IMXT plans.  
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Contralateral breast dose metrics (Dmax, Dmean, and V5Gy) for IM-BECT and VMAT plans 
are shown in Table C.4. The most clinically significant change was the average Contralateral 
Breast V5Gy (-19.3% change). A reduced volume of low dose bath (<5 Gy) to contralateral breast 
is expected to reduce the risk of formation of second malignant neoplasms. The other 
contralateral breast metrics all show an improvement in plan quality with the use of IM-
BECT+IMXT. 
The biological metrics (PTV TCP, Total Lung NTCP, Total Lung SCCP, Heart NTCP, 
Myocardium NTCP, and Contralateral Breast SCCP) compared between IM-BECT+IMXT and 
VMAT plans are shown in Table C.5. The most notable difference was for average Contralateral 
Breast SCCP (-2.2% change) with the use of IM-BECT+IMXT. This improvement is related to 
the -19.3% reduction of Contralateral Breast V5Gy for IM-BECT+IMXT compared to VMAT. 
Comparisons of all other biological metrics also showed improved plan quality with the use of 
IM-BECT+IMXT.  
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Table C.1 PTV Dmin, Dmax, V107%, DHI, and CI; and TV-V110% 
 PTV TV 
Energy Patient 
-Plan 
Dmin Dmax V107% DHI CI V110% 
 [Gy] [Gy] [%]   [%] 
6 MV CW1-V 11.7 54.3 0.2 0.16 0.68 0.0 
16 MeV CW1-IM 45.8 54.6 6.4 0.18 0.37 2.2 
6 MV CW2-V 18.5 53.2 0.0 0.13 0.73 0.0 
13 MeV CW2-IM 45.6 53.7 2.6 0.16 0.33 3.5 
6 MV CW3-V 22.8 53.3 0.0 0.13 0.65 0.0 
13 MeV CW3-IM 45.1 53.9 5.2 0.18 0.33 0.6 
6 MV CW4-V 24.2 54.3 0.0 0.12 0.72 0.0 
16 MeV CW4-IM 45.6 54.4 6.0 0.18 0.34 8.7 
6 MV CW5-V 16.7 54.3 0.1 0.15 0.67 0.0 
16 MeV CW5-IM 46.0 53.7 2.6 0.15 0.35 2.8 
6 MV CW6-V 29.7 53.1 0.0 0.13 0.67 0.0 
13 MeV CW6-IM 45.4 53.1 0.9 0.15 0.34 0.4 
6 MV CW7-V 28.1 53.0 0.0 0.10 0.77 0.0 
16 MeV CW7-IM 46.3 52.9 0.9 0.13 0.35 0.0 
6 MV CW8-V 22.1 52.7 0.0 0.12 0.68 0.0 
13 MeV CW8-IM 45.4 52.8 0.3 0.15 0.35 1.1 
6 MV CW9-V 13.9 52.9 0.0 0.10 0.69 0.0 
16 MeV CW9-IM 45.8 54.4 4.9 0.17 0.35 4.0 
AVG VMAT 20.9 53.5 0.0 0.13 0.70 0.0 
σ VMAT 6.1 0.7 0.1 0.02 0.04 0.0 
AVG IM-BECT 45.7 53.7 3.3 0.16 0.35 2.6 
σ IM-BECT 0.4 0.7 2.4 0.02 0.01 2.7 
Change 24.8 0.2 3.3 0.03 -0.35 2.6 
Note: V and IM indicate VMAT and IM-BECT+IMXT plans, respectively. Change equals 
AVG IM-BECT – AVG VMAT, where AVG VMAT and AVG IM-BECT are metric 
averages for VMAT and IM-BECT+IMXT plans, respectively. 
190 
 
 
  
Table C.2 Lung Dmax, Dmean, SD, V5Gy, V10Gy, and V20Gy 
 Lung 
Energy Patient 
-Plan 
Dmax Dmean V5Gy V10Gy V20Gy 
 [Gy] [Gy] [%] [%] [%] 
6 MV CW1-V 49.9 8.7 41.4 23.5 13.4 
16 MeV CW1-IM 46.0 7.6 26.6 21.1 15.7 
6 MV CW2-V 48.5 8.5 41.3 22.7 13.5 
13 MeV CW2-IM 43.4 6.3 22.9 19.0 13.8 
6 MV CW3-V 51.2 8.8 41.7 22.9 13.1 
13 MeV CW3-IM 43.8 8.3 30.2 24.8 18.6 
6 MV CW4-V 47.4 9.2 50.6 29.5 14.1 
16 MeV CW4-IM 37.7 5.0 19.9 15.1 10.0 
6 MV CW5-V 49.6 8.4 41.3 22.7 13.3 
16 MeV CW5-IM 46.9 8.2 29.5 23.4 16.4 
6 MV CW6-V 51.2 9.9 54.7 26.7 14.3 
13 MeV CW6-IM 47.8 8.7 28.2 22.7 17.8 
6 MV CW7-V 47.0 8.6 47.7 25.3 11.0 
16 MeV CW7-IM 46.5 7.7 26.0 20.4 15.0 
6 MV CW8-V 50.0 8.0 39.1 22.1 12.4 
13 MeV CW8-IM 44.7 7.4 27.6 22.4 16.7 
6 MV CW9-V 46.3 8.0 37.4 23.4 12.1 
16 MeV CW9-IM 46.3 7.0 23.5 18.6 13.6 
AVG VMAT 49.0 8.7 43.9 24.3 13.0 
σ VMAT 1.8 0.6 5.8 2.4 1.0 
AVG IM-BECT 44.8 7.4 26.1 20.8 15.3 
σ IM-BECT 3.0 1.1 3.4 3.0 2.6 
Change -4.2 -1.3 -17.8 -3.5 2.3 
Note: V and IM indicate VMAT and IM-BECT+IMXT plans, respectively. Change equals 
AVG IM-BECT – AVG VMAT, where AVG VMAT and AVG IM-BECT are metric 
averages for VMAT and IM-BECT+IMXT plans, respectively. 
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Table C.3 Heart Dmax, Dmean, V5Gy, V10Gy, V22.5Gy, and V30Gy 
 Heart 
Energy Patient 
-Plan 
Dmax Dmean V5Gy V10Gy V22.5Gy V30Gy 
 [Gy] [Gy] [%] [%] [%] [Gy] 
6 MV CW1-V 43.0 9.0 56.4 25.8 9.7 5.1 
16 MeV CW1-IM 24.4 5.3 28.7 17.4 3.1 0.2 
6 MV CW2-V 41.3 10.2 82.8 25.1 11.0 7.2 
13 MeV CW2-IM 23.2 3.7 19.5 11.9 2.3 0.2 
6 MV CW3-V 40.2 7.0 43.3 15.6 5.5 1.9 
13 MeV CW3-IM 24.8 4.2 22.2 13.8 3.2 0.3 
6 MV CW4-V 38.4 9.2 59.8 29.4 9.2 1.8 
16 MeV CW4-IM 16.5 2.9 11.9 5.5 0.5 0.0 
6 MV CW5-V 47.5 10.0 64.9 24.9 12.2 9.1 
16 MeV CW5-IM 26.3 4.5 23.0 14.2 3.8 0.8 
6 MV CW6-V 49.1 10.9 85.2 29.2 11.5 7.8 
13 MeV CW6-IM 30.5 5.4 27.2 18.1 6.1 2.2 
6 MV CW7-V 43.6 9.4 68.6 26.7 8.7 3.8 
16 MeV CW7-IM 34.4 8.3 39.9 28.0 12.4 5.0 
6 MV CW8-V 43.4 9.3 67.6 26.6 10.1 4.6 
13 MeV CW8-IM 25.1 3.9 20.5 13.0 3.2 0.5 
6 MV CW9-V 39.0 9.2 73.3 24.1 9.9 3.8 
16 MeV CW9-IM 23.2 5.2 28.9 16.1 2.3 0.2 
AVG VMAT 42.8 9.4 66.9 25.3 9.8 5.0 
σ VMAT 3.6 1.1 13.0 4.1 1.9 2.6 
AVG IM-BECT 25.4 4.8 24.7 15.3 4.1 1.0 
σ IM-BECT 5.0 1.5 7.8 6.0 3.5 1.6 
Change -17.4 -4.6 -42.2 -10.0 -5.7 -4.0 
Note: V and IM indicate VMAT and IM-BECT+IMXT plans, respectively. Change equals 
AVG IM-BECT – AVG VMAT, where AVG VMAT and AVG IM-BECT are metric 
averages for VMAT and IM-BECT+IMXT plans, respectively. 
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Table C.4 Contralateral Breast Dmax, Dmean, and V5Gy 
 Contralateral Breast 
Energy Patient 
-Plan 
Dmax Dmean V5Gy 
 [Gy] [Gy] [%] 
6 MV CW1-V 18.7 3.8 22.6 
16 MeV CW1-IM 15.4 1.1 5.4 
6 MV CW2-V 24.4 2.7 9.3 
13 MeV CW2-IM 10.6 0.8 3.4 
6 MV CW3-V 32.2 5.8 45.1 
13 MeV CW3-IM 10.8 0.8 3.2 
6 MV CW4-V 19.7 4.2 19.4 
16 MeV CW4-IM 20.2 1.3 4.9 
6 MV CW5-V 21.5 2.4 11.2 
16 MeV CW5-IM 8.8 0.7 3.1 
6 MV CW6-V 41.4 4.7 24.8 
13 MeV CW6-IM 31.3 1.9 7.4 
6 MV CW7-V 21.6 3.1 17.3 
16 MeV CW7-IM 12.9 1.0 4.0 
6 MV CW8-V 25.7 4.0 27.8 
13 MeV CW8-IM 5.6 0.5 2.2 
6 MV CW9-V 38.9 4.9 40.3 
16 MeV CW9-IM 29.6 2.5 10.9 
AVG VMAT 27.1 4.0 24.2 
σ VMAT 8.4 1.1 12.1 
AVG IM-BECT 16.1 1.2 4.9 
σ IM-BECT 9.1 0.6 2.7 
Change -11.0 -2.8 -19.3 
Note: V and IM indicate VMAT and IM-BECT+IMXT plans, respectively. Change equals 
AVG IM-BECT – AVG VMAT, where AVG VMAT and AVG IM-BECT are metric 
averages for VMAT and IM-BECT+IMXT plans, respectively. 
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Table C.5 Biological Metrics for TCP, NTCP, and SCCPl (linear model) 
 PTV Total Lung Heart Myo-
cardium 
Contralateral 
Breast 
Patient 
-Plan 
TCP NTCP SCCPle NTCP NTCP SCCPl 
[%] [%] [%] [%] [%] [%] 
CW1-V 97.6 2.7 14.9 0.7 1.0 3.0 
CW1-IM 99.8 2.1 12.8 0.1 0.1 0.9 
CW2-V 97.5 2.7 14.7 1.0 1.5 2.1 
CW2-IM 99.9 1.6 10.6 0.1 0.1 0.6 
CW3-V 99.8 2.8 15.1 0.3 0.4 4.6 
CW3-IM 99.7 2.5 14.0 0.1 0.1 0.6 
CW4-V 99.6 3.0 15.7 0.3 0.6 3.2 
CW4-IM 99.0 1.2 8.5 0.0 0.0 1.0 
CW5-V 94.8 2.6 14.4 1.7 3.0 1.9 
CW5-IM 99.9 2.4 13.7 0.1 0.2 0.5 
CW6-V 99.7 3.4 16.8 1.6 2.4 3.7 
CW6-IM 99.9 2.7 14.6 0.3 0.4 1.5 
CW7-V 99.7 2.7 14.6 0.5 0.8 2.5 
CW7-IM 99.9 2.2 12.9 0.7 1.0 0.8 
CW8-V 99.8 2.4 13.8 0.6 1.0 3.2 
CW8-IM 99.6 2.1 12.5 0.1 0.1 0.4 
CW9-V 99.4 2.4 13.7 0.5 0.8 3.9 
CW9-IM 99.9 1.9 11.7 0.1 0.1 2.0 
AVG-V 98.7 2.7 14.9 0.8 1.3 3.1 
σ-V 1.7 0.3 1.0 0.5 0.9 0.9 
AVG-IM 99.7 2.1 12.4 0.2 0.2 0.9 
σ-IM 0.3 0.5 1.9 0.2 0.3 0.5 
Change 1.0 -0.6 -0.5 -0.6 -1.1 -2.2 
Note: V and IM indicate VMAT and IM-BECT+IMXT plans, respectively. Change equals 
AVG-IM – AVG-V, where AVG-V and AVG-IM are metric averages for VMAT and IM-
BECT+IMXT plans, respectively. 
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Statistical Analysis 
The results of a statistical analysis performed on the metrics compared between IM-
BECT+IMXT and VMAT plans are shown in Table C.6 through Table C.9. Only the metrics that 
were found to be statistically significantly different are reported in these tables. All biological 
metrics results have been moved to the table for their respective PTV or OAR.  
Table C.6 shows that PTV Dmin, V107%, CI, DHI; and TV-V110% differences were all 
statistically significant (p=0.004, except for TV-V110% for which p=0.007). The statistically 
significant change (24.8 Gy with IM-BECT+IMXT) in Dmin from 20.9 Gy to 45.7 Gy shows that 
while VMAT coverage is statistically significantly more conformal than IM-BECT+IMXT (0.70 
and 0.35 for VMAT vs IM-BECT+IMXT, respectively) there were on average some regions of 
the PTVs that received less than 42% of the prescribed dose using VMAT compared to 91.4% 
Table C.6 PTV Dmin, V107%, CI, DHI; and TV-V110% 
 PTV TV 
 Dmin V107% CI DHI V110% 
 [Gy] [%]   [%] 
AVG-VMAT* 20.9 0.0 0.70 0.13 0.0 
 σ-IM 6.1 0.1 0.04 0.02 0.0 
AVG-IM-BECT* 45.7 3.3 0.35 0.16 2.6 
 σ-IM 0.4 2.4 0.01 0.02 2.7 
Change* 24.8 3.3 -0.35 0.03 2.6 
p-value 0.004 0.004 0.004 0.004 0.007 
 
*Change equals AVG-IM-BECT – AVG-VMAT, where AVG-VMAT and AVG-IM-BECT 
are metric averages for Heins’ VMAT plans (Heins 2016) and the IM-BECT+IMXT plans 
generated in this study, respectively. 
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using IM-BECT+IMXT. Despite the large reduction in average Dmin with VMAT, there was still 
a statistically significant reduction in the PTV DHI (0.13 and 0.16 for VMAT vs IM-
BECT+IMXT, respectively).  The most clinically significant differences in PTV metrics that 
were also statistically significant were the changes in V107% and TV-V110%, which increased on 
average by 3.3% and 2.6% with the use of IM-BECT+IMXT. In the analysis of the PTV metrics, 
the differences between the D95% and V95% were not compared as these metrics were expected to 
be similar because of them being tightly controlled by similar plan normalization methods used 
in each study (i.e. 95% volume of the PTV received 95% prescribed dose). 
Table C.7 shows that Lung Dmean, Dmax, V5Gy, NTCP, and SCCPl were all statistically 
significantly different (p=0.004 for each). The only lung metrics that were statistically 
significantly different are all improvements with the use of IM-BECT+IMXT. Despite a 
statistically insignificant reduction in average Lung V20Gy with the use of VMAT, both Lung 
NTCP and SCCPl were found to be statistically significantly reduced by small margins (-0.6% 
and -2.5%, respectively) with the use of IM-BECT+IMXT. 
Table C.7 Lung Dmean, Dmax, V5Gy, NTCP, and SCCPl 
 Lung  
 Dmean Dmax V5Gy NTCP SCCPl 
 [Gy] [Gy] [%] [%] [%] 
AVG-VMAT* 8.7 49.0 43.9 2.7 14.9 
 σ-VMAT 0.6 1.8 5.8 0.3 1 
AVG-IM-BECT* 7.4 44.8 26.1 2.1 12.4 
 σ-IM-BECT 1.1 3.0 3.4 0.5 1.9 
Change* -1.3 -4.2 -17.8 -0.6 -2.5 
p-value 0.004 0.004 0.004 0.004 0.004 
 
*Change equals AVG-IM-BECT – AVG-VMAT, where AVG-VMAT and AVG-IM-BECT 
are metric averages for Heins’ VMAT plans (Heins 2016) and the IM-BECT+IMXT plans 
generated in this study, respectively. 
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Table C.8 shows that changes in average Myocardium NTCP (p=0.008); Heart Dmean, 
Dmax, and V5Gy (p=0.004 for each); V10Gy, V30Gy, V5Gy, and NTCP (p=0.008 for each); and V22.5Gy 
(p=0.012) were all statistically significant. These differences in myocardium and heart metrics 
were all statistically significant improvements in plan quality with the use of IM-BECT+IMXT. 
The statistically significant reductions in average heart Dmean, V22.5Gy, and V30Gy (-4.6 Gy, -5.7%, 
and -1.0%, respectively) with IM-BECT+IMXT are clinically significant and can be related to 
the statistically significantly reduced Myocardium and Heart NTCPs (-0.6% each).   
Table C.9 shows that Contralateral Breast Dmean, V5Gy, and SCCPl (p=0.0.004); and Dmax 
and Dmax (p=0.008) were all statistically significantly different. These Contralateral Breast 
metrics were all statistically significant improvements in plan quality with the use of IM-
BECT+IMXT. The statistically significant reduction in average Contralateral Breast V5Gy (-
19.3%) with the use of IM-BECT+IMXT is potentially clinically significant as it shows a large 
reduction in the low dose bath (<5 Gy) compared to VMAT. This difference is also in agreement 
Table C.8 Myocardium NTCP; and Heart Dmean, Dmax, V5Gy, V10Gy, V22.5Gy, V30Gy and NTCP 
 Myocardium Heart 
 NTCP Dmean Dmax V5Gy V10Gy V22.5Gy V30Gy NTCP 
 [%] [Gy] [Gy] [%] [%] [%] [%] [%] 
AVG-VMAT* 2.7 9.4 42.8 66.9 25.3 9.8 5 0.8 
 σ-VMAT 0.3 1.1 3.6 13.0 4.1 1.9 2.6 0.5 
AVG-IM-BECT* 2.1 4.8 25.4 24.7 15.3 4.1 1.0 0.2 
 σ-IM-BECT 0.5 1.5 5 7.8 6.0 3.5 1.6 0.2 
Change* -0.6 -4.6 -17.4 -42.2 -10.0 -5.7 -1.0 -0.6 
p-value 0.008 0.004 0.004 0.004 0.008 0.012 0.008 0.008 
 
*Change equals AVG-IM-BECT – AVG-VMAT, where AVG-VMAT and AVG-IM-BECT 
are metric averages for Heins’ VMAT plans (Heins 2016) and the IM-BECT+IMXT plans 
generated in this study, respectively. 
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 with the statistically significant difference in IM-BECT+IMXT and VMAT Contralateral Breast 
SCCPl (3.1% and 0.9% for VMAT vs IM-BECT+IMXT, respectively).  
Conclusion 
 Prior VMAT studies (Ashenafi 2010, Nichols 2014, and Heins 2016) have shown VMAT 
and Tomotherapy plans are capable of delivering highly conformal and homogeneous PTV dose 
distributions in the setting of PMRT. These studies also showed that the low dose bath to NT is 
considerably larger than that of a mixed-beam plan incorporating electron beams. The present 
study focused primarily on the differences between IM-BECT+IMXT and BECT+IMXT 
treatment plans in the setting of left sided PMRT. A secondary goal was to perform a statistical 
analysis comparing plan metrics computed for IM-BECT+IMXT plans generated in this study 
with VMAT  plans (Heins 2016) generated for the same patient cohort. 
  This statistical analysis has shown that for the VMAT plans there were indeed a 
statistically significantly better PTV DHI, CI, V107%, and TV-V110% compared to IM-
Table C.9 Contralateral Breast Dmean, Dmax, V5Gy, and SCCPl 
 Contralateral Breast 
 Dmean Dmax V5Gy SCCPl 
 [Gy] [Gy] [%] [%] 
AVG-VMAT* 4 27.1 24.2 3.1 
 σ-VMAT 1.1 8.4 12.1 0.9 
AVG-IM-BECT* 1.2 16.1 4.9 0.9 
 σ-IM-BECT 0.7 9.1 2.7 0.5 
Change* -2.8 -11.0 -19.3 -2.2 
p-value 0.004 0.008 0.004 0.004 
 
*Change equals AVG-IM-BECT – AVG-VMAT, where AVG-VMAT and AVG-IM-BECT 
are metric averages for Heins’ VMAT plans (Heins 2016) and the IM-BECT+IMXT plans 
generated in this study, respectively. 
 
198 
 
BECT+IMXT, as expected. For the VMAT plans compared to IM-BECT+IMXT plans, the PTV 
DHI, V107%, and TV-V110% were reduced on average by -0.35, -3.3%, and -2.6%, respectively, 
while average DHI increased by 0.03. These differences were all found to be statistically 
significant advantages of VMAT in terms of PTV coverage. However,  almost every OAR metric 
compared in this analysis showed statistically significant advantages with the use of IM-
BECT+IMXT, largely due to the reduction in low dose bath (<5 Gy) to NT.  
The most clinically significant of these differences for Heart were Dmean, V22.5Gy, and 
V30Gy (-4.6 Gy, -5.7%, and -1.0%, respectively). These reductions were associated with 
somewhat less Myocardium and Heart NTCP (-0.6% each), which were each statistically 
significant. Lung V20Gy was the only OAR metric that showed an improvement with VMAT on 
average (-2.3% change). However, this change was found to be statistically insignificant. 
Furthermore, statistically significant reductions in total Lung V5Gy and V10Gy (-17.8% and -3.5%, 
respectively) were met with statistically significant reductions in Lung NTCP and SCCPl (-0.6% 
and -0.5%) for IM-BECT+IMXT compared to VMAT. Because of the reduced low dose bath for 
IM-BECT+IMXT compared to VMAT, Contralateral Breast V5Gy was reduced from 24.2% to 
4.9% (-19.3% change). Reductions in Contralateral Breast V5Gy (24.2% and 4.9% for VMAT vs 
IM-BECT+IMXT), as well as SCCPl (3.1% and 0.9% for VMAT vs IM-BECT+IMXT) were 
each also statistically significant.  
These comparisons highlight the benefit of improving PTV dose homogeneity for mixed-
beam electron techniques. Further study is required to determine if improvement in PTV dose 
homogeneity for IM-BECT+IMXT plans can be achieved such that the difference between IM-
BECT+IMXT and VMAT dose homogeneity is clinically insignificant.   
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